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A-C   Anger control 
A-I   Anger-in 
A-O   Anger-out 
AA   Angry afterthoughts 
AM   Angry memories 
ARS    Anger rumination scale 
AWMF   Association of the scientific medical societies in Germany 
CBT   Cognitive-behavioral therapy 
CNS   Central nervous system 
CRF   Corticotropin releasing factor 
CWP   Chronic widespread pain syndrome 
FDA   Federal drug administration 
FIQ    Fibromyalgia impact questionnaire 
FMS    Fibromyalgia syndrome 
FOO    Forgiveness of others 
FOS   Forgiveness of self 
HFS   Heartland forgiveness scale 
HPA   Hypothalamic – pituitary – adrenal 
LC-NE   Locus coeruleus-norepinephrine 
MBSR   Mindfulness-based stress reduction 
PTSD   Posttraumatic stress disorder 
S-A   State anger  
STAXI    State trait anger expression inventory 
T-A   Trait anger 
ToR   Thoughts of revenge 
UoC   Understanding of causes 
VAS   Visual analogue scale 
PCS   Short form 12 physical component summary  
MCS   Short form 12 mental component summary 
HADS    Hospital anxiety and depression scale 
QOLS   Quality of life scale 
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Fibromyalgia syndrome (FMS) causes chronic multifocal musculoskeletal pain and 
sensitivity to touch, along with other symptoms like fatigue and sleep problems. It 
affects over two percent of the population, mostly women. Common comorbidities 
are depression and anxiety. The disease is diagnosed by first ruling out other pos-
sible somatic causes and then using the New Clinical Fibromyalgia Diagnostic Cri-
teria Questionnaire along with assessing fatigue and sleeping disorders. Three 
pathogenetic factors have been described: alterations of central processing of sen-
sory input, neuroendocrine abnormalities and peripheral pain generators. There is 
no causal treatment available and only few therapies offer some symptom allevia-
tion. Ideally, therapies should be polymodal and should include at least one acti-
vating element (such as physical exercise) as well as at least one psychological 
intervention. Drug therapy alleviates the symptoms somewhat in only some of the 
patients, though off-label use of some antidepressants and neuroleptic drugs can 
be discussed.  
This study focuses on the association between FMS and psychosocial and psy-
chovegetative constructs such as forgiveness, anger and anger rumination. For-
giveness is described as a multidimensional phenomenon which involves the in-
tentional letting go of a person´s negative thoughts, feelings and actions towards 
someone who committed a wrong against them. Prior studies showed a link to 
FMS. Anger is defined as a psychovegetative mechanism to defend oneself when 
threatened. Prior studies have established a relationship between anger, espe-
cially anger which is directed inwards, and FMS. Anger rumination describes re-
curring thoughts of a negative event. The detrimental effects of anger rumination 
have been traced in various psychological conditions (e.g. depression); to our 
knowledge, anger rumination in patients with FMS has not been the scope of any 
studies, yet.  
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Designed to help survive threatening situations, stress is nowadays considered a 
perceived overload of life´s demands. Chronic psychovegetative activation, which 
is typically caused by too much stress, has been linked to poor health (e.g. cardi-
ovascular diseases, strokes, depression) and hyperalgesia. As stressful life expe-
riences are common in patients with FMS, a connection between stress levels and 
symptom severity could be established.  
 
Methods 
In this cross-sectional study, 173 FMS patients and 81 healthy individuals com-
pleted a questionnaire battery consisting of sociodemographic questions (inquiring 
about the subjects’ age, gender, religion, marital status and educational status), 
several pain scales (assessing pain history, pain intensity and pain frequency) as 
well as the Fibromyalgia impact questionnaire (FIQ), the quality of life scale 
(QOLS), the short form health survey 12 (SF-12 with physical component summary 
(PCS) and mental component summary (MCS)), hospital anxiety and depression 
scale (HADS with subscales anxiety and depression), Mauger forgiveness of 
self and others, state trait anger expression inventory (STAXI) and the anger 
rumination scale (ARS).  
 
Results 
The groups differed significantly on various counts of their pain, symptom burden 
and their life quality (pain duration* FMS patients (FMS) 18.07 years, controls 
(CTRL) 1,05 years; pain today* FMS 6,18, CTRL 0,49; pain severity last three 
months* FMS 6,76, CTRL 0,95; QOLS* FMS 66,27, CTRL 88,47; FIQ* FMS 50,22, 
CTRL 11,98; HADS subscale anxiety* FMS 10,59, CTRL 4,77; HADS depression* 
FMS 9,42; CTRL 2,7; SF-12 12 PCS* FMS 30,24, CTRL 50,48; SF-12 MCS* FMS 
35,62, CTRL 50,34).  
Compared with the healthy controls, FMS patients reported significantly lower 
levels of forgiveness of self (FMS 38,43, CTRL 30,51), whereas no significant 
difference regarding forgiveness of others was detected between the two groups  
(FMS 36,59, CTRL 33,61).  
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Some significant differences were observed regarding anger as measured by the 
state and trait anger inventory. FMS patients were scoring significantly higher on 
most subscales (state anger* FMS 15,36, CTRL 11,59; trait anger* FMS 21,75, 
CTRL 19,16; anger-in* FMS 20,35, CTRL 15,51; anger-out FMS 13,49, CTRL 
13,39; anger control FMS 22,21, CTRL 23,25). Moreover, we found significant 
differences on all subscales of the anger rumination scale which indicate more 
angry rumination in FMS patients (angry afterthoughts* FMS 2,44, CTRL 1,83, 
thoughts of revenge* FMS 1,60, CTRL 1,45; angry memories* FMS 2,50, CTRL 
1,80; understanding causes* FMS 2,50, CTRL 2,10; anger rumination scale total* 
FMS 2,26, CTRL 1,80). Self-forgiveness showed several significant Pearson 
correlation coefficients r with quality of life and symptom burden indices (FIQ: r 
=0,30*; HADS anxiety r=0,58*; HADS depression r=0,45*; SF-12 PCS r=0,07; SF-
12 MCS r=-0,41*, QOLS r=-0,43*). Forgiveness of others also showed significant 
correlations (FIQ: r=0,07; HADS-anxiety r=0,23*; HADS depression r=0,22*; SF-
12 PCS r=-0,02, SF-12 MCS r=-0,09; QOLS r=-0,29*). Of all STAXI anger 
subscales, state anger correlated most with high symptom expression, poor mental 
health and low quality of life (FIQ r=0,31*; HADS anxiety r=0,33*; HADS 
depression r=0,37*; SF-12 PCS r=-0,10; SF-12 MCS r=-0,30*; QOLS r=-0,40*), 
followed by trait anger, anger in and anger out. Of all ARS subscales, angry 
afterthoughts correlated most with high FMS symptom expression, low mental 
health and low quality of life life (FIQ r=0,24*; HADS anxiety r=0,46*; HADS 
depression r=0,43*; SF-12 PCS r=0,05; SF-12 MCS r=-0,23*; QOLS r=-0,31*).  
* statistically significant 
 
Discussion 
FMS patients showed a lower capacity to forgive altogether, compared to healthy 
individuals. The results suggest that especially forgiving themselves is difficult for 
FMS patients. Prior studies have established behavioral patterns centered around 
exceptionally high self-expectations, which can result in stern self-criticism when 
they are not met. The literature also links high levels of self-criticism to grave symp-
tom severity in chronic pain patients. Therefore, it seems likely that FMS patients 
12 
could potentially decrease their disease burden by increasing their self-for-
giveness. Furthermore, the reduced ability to forgive others results in anger, re-
sentment and distress. These sentiments have been linked to a decline of close 
personal relationships. Because strong relational backup has been demonstrated 
to facilitate the rehabilitation and the adaption to chronic disease, forgiveness of 
others is likely to positively influence FMS. Anger, especially anger, which is di-
rected inward, has been demonstrated to amplify the level of preexisting pain and 
worsen depressive symptoms. Forgiveness has shown to have a diminishing effect 
on anger expression while boosting anger control. Hence, it seems likely that a 
forgiveness-based intervention focused on reducing the internalization of anger 
and educating the patients on how to express their anger healthily would be prom-
ising for patients with FMS. As with anger, prior research suggests a similar con-
nection of anger rumination to symptom burden. Moreover, our findings show an 
inverse correlation of forgiveness and angry rumination scores. It seems likely that 
angry rumination could be decreased by an intervention centered around for-
giveness, which, again, could benefit FMS patients. 
We suggest a longitudinal study which assesses anger and stress levels in the 
course of a forgiveness intervention. This would help further our understanding of 
how FMS, forgiveness, anger and anger rumination are interwoven. Potentially, it 




Das Fibromyalgiesyndrom (FMS) gehört zu den chronischen Schmerzsyndromen 
und verursacht neben multifokalen muskuloskeletalen Schmerzen auch Berüh-
rungsempfindlichkeit und weitere Symptome wie Abgeschlagenheit und Schlafstö-
rungen. FMS ist eine weitverbreitete Erkrankung und betrifft etwa zwei Prozent der 
Bevölkerung, hauptsächlich Frauen. Zu den Komorbiditäten gehören unter ande-
rem Depression und Ängstlichkeit.  
Um die Erkrankung zu diagnostizieren müssen zuerst andere somatische Ursa-
chen für die Beschwerden ausgeschlossen werden. Dann kann sie mittels des 
Fragebogens New Clinical Fibromyalgia Diagnostic Criteria Questionnaire und 
dem Erfragen von Fatigue-Beschwerden und Schlafstörungen diagnostiziert wer-
den. Bezüglich der Pathogenese sind drei Faktoren bekannt: Veränderungen der 
zentralen sensorischen Signalverarbeitung, Aberrationen des neuroendokrinen 
Systems und das Vorhandensein peripherer Schmerzgeneratoren. Eine Kausal-
therapie steht nicht zur Verfügung; nur wenige Therapien führen zu etwas redu-
zierten Symptomen. Am vielversprechendsten sind polymodale Therapieansätze, 
die mindestens ein aktivierendes Element (z.B. Ausdauertraining) mit mindestens 
einer psychologischen Intervention kombinieren. Eine medikamentöse Therapie 
mit Analgetika oder bestimmten Antidepressiva und Neuroleptika als off-label Ver-
ordnung führt nur bei einem Teil der Pateinten zu einer leichten Linderung der 
Symptome.  
Diese Studie soll einen Einblick verschaffen, inwiefern Vergebung, Ärger und 
Stress mit FMS vergesellschaftet sind. Vergebung, ein multidimensionales Phäno-
men, meint das absichtliche Loslassen von negativen Gedanken, Gefühlen und 
Taten gegenüber einer Person, die sich etwas zu Schulden hat kommen lassen. 
In der Literatur wurde eine Verbindung von Vergebung mit Depression beschrie-
ben. Auch der positive Einfluss von Vergebung auf chronische Schmerzen und 
Stresslevels ist dokumentiert.  
Ärger wurde beschrieben als psychovegetativer Verteidigungsmechanismus zur 




besonders jener, der gegen die Person selbst gerichtet ist, mit FMS ist vorbe-
schrieben. Ärger-Rumination, also das „Wiederkäuen“ von Ärger-Erlebnissen der 
Vergangenheit, konnte unter anderem mit Depression in Verbindung gebracht 
werden. Eine Untersuchung der Beziehung von Ärger-Rumination und FMS ist bis-
her nicht erfolgt.  
Stress, der ursprünglich dazu diente in Gefahrensituationen zu überleben, wird 
heute als die empfundene Überforderung mit den Herausforderungen des Lebens 
gedeutet. Chronische psychovegetative Aktivierung, die typischerweise durch 
langanhaltenden Stress hervorgerufen wird, kann zu verschiedenen Erkrankungen 
(u.a. kardiovaskuläre Erkrankungen, Depression, Hyperalgesie) führen. Traumati-
sche Lebenserfahrungen sind bei FMS Patienten häufig; eine Verbindung von 
Stresslevels und FMS Symptomschwere wurde bereits beschrieben.  
 
Methoden 
In dieser Querschnittsstudie wurden Fragebögen von 173 FMS Patienten und ei-
ner Kontrollgruppe von 81 gesunden Personen ausgefüllt. Inhalt der Fragebögen 
waren neben sozioökonomische Informationen (Alter, Geschlecht, Religion, Be-
ziehungs- und Bildungsstatus) und mehreren Schmerzskalen (vergangene 
Schmerzereignisse, Schmerzintensität und -frequenz) der Fibromyalgia Impact 
Questionnaire (FIQ), die Quality of Life Scale (QOLS), die Short Form Health Sur-
vey (SF-12 mit den Subskalen Physical Component Summary (PCS) und Mental 
Component Summary (MCS)), die Hospital Anxiety and Depression Scale (HADS 
mit den Subskalen Ängstlichkeit und Depression), Mauger forgiveness of Self and 
Others, das State Trait Anger Expression Inventory (STAXI) und die Anger Rumi-
nation Scale (ARS).  
 
Ergebnisse 
Signifikante Unterschiede zeigten sich bei den Erhebungen von Schmerz, Symp-
tombelastung und Lebensqualität (Mittelwerte: Schmerzdauer* FMS-Patienten 
(FMS) 18,07 Jahre, Kontrollgruppe (KG) 1,05 Jahre; Schmerzen heute* FMS 6,18 




FMS 66,27, KG 88,47; FIQ* FMS 50,22, KG 11,98; HADS Subskala Ängstlichkeit* 
FMS 10,59, KG 4,77; HADS Subskala Depression* FMS 9,42; KG 2,7; SF-12 12 
PCS* FMS 30,24, KG 50,48; SF-12 MCS* FMS 35,62, KG 50,34). Im Vergleich zu 
den gesunden Kontrollpersonen wiesen die FMS-Patienten eine signifikant niedri-
gere Selbstvergebungsfähigkeit auf,  (Mittelwerte: FMS 38,43, KG 30,51). Bezüg-
lich der Vergebungsfähigkeit anderer zeigte sich kein signifikanter Unterschied.   
(FMS 36,59, KG 33,61). Bei den Ärgerskalen STAXI und ARS konnten ebenfalls 
signifikante Unterschiede detektiert werden; insgesamt zeigten die FMS-Patienten 
deutlich höhere Ärgerscores (Mittelwerte: Zustandsärger* FMS 15,36, KG 11,59; 
Ärger als Eigenschaft* FMS 21,75, KG 19,16; nach innen gerichteter Ärger* FMS 
20,35, KG 15,51; nach außen gerichteter Ärger FMS 13,49, KG 13,39; Ärgerkon-
trolle FMS 22,21, KG 23,25; nachträglicher Ärger* FMS 2,44, KG 1,83, Rachege-
danken FMS 1,60, KG 1,45; Ärgererinnerungen* FMS 2,50, KG 1,80; Ursachen-
verständnis* FMS 2,50, KG 2,10; ARS insgesamt* FMS 2,26, KG 1,80). Selbstver-
gebung zeigte zahlreiche signifikante Pearson Korrelationenskoefizienten r mit Le-
bensqualitäts- und Symptomschwereindices (FIQ r = 0,30*; HADS Ängstlichkeit 
r=0,58*; HADS Depression r=0,45*; SF-12 PCS r=0,07; SF-12 MCS r=-0,41*, 
QOLS r=-0,43*). Vergebung von anderen zeigte ebenfalls einige signifikante Kor-
relationen (FIQ r=0,07; HADS Ängstlichkeit r=0,23*; HADS Depression r=0,22*; 
SF-12 PCS r=-0,02, SF-12 MCS r=-0,09; QOLS r=-0,29*). Von den STAXI Sub-
skalen zeigte Zustandsärger die höchsten Korrelationen mit Symptomschwere, 
beeinträchtigter mentaler Gesundheit und niedriger Lebensqualität (FIQ r=0,31*; 
HADS Ängstlichkeit r=0,33*; HADS Depression r=0,37*; SF-12 PCS r=-0,10; SF-
12 MCS r=-0,30*; QOLS r=-0,40*), gefolgt von Eigenschaftsärger, Ärger, der nach 
innen und Ärger der nach außen gerichtet ist. Von den ARS Subskalen zeigte die 
Skala nachträglicher Ärger die höchste Korrelation mit Symptomschwere, beein-
trächtigter mentaler Gesundheit und niedriger Lebensqualität (FIQ r=0,24*; HADS 
Ängstlichkeit r=0,46*; HADS Depression r=0,43*; SF-12 PCS r=0,05; SF-12 MCS 
r=-0,23*; QOLS r=-0,31*).  






FMS Patienten zeigen im Vergleich zur Kontrollgruppe eine insgesamt niedrigere 
Vergebungsfähigkeit; dabei ist insbesondere die Selbstvergebung eingeschränkt. 
Frühere Studien konnten bei FMS Patienten eine hohe Erwartungshaltung an sich 
selbst aufzeigen, die, sollte sie nicht erfüllt werden, in strenger Selbstkritik mündet. 
Zudem konnte bei chronischen Schmerzpatienten eine Korrelation von Selbstkritik 
und Symptomschwere aufgezeigt werden. Daher wäre es vorstellbar, dass Selbst-
vergebung dabei helfen könnte, den eigenen Unzulänglichkeiten mit mehr Milde 
zu begegnen und so auch die FMS-bezogene Schmerzsymptome zu reduzieren.  
Die verminderte Vergebungsfähigkeit resultiert in Ärger, Ressentiment und Stress. 
Diese Gefühle stehen in Verbindung mit einer Abnahme der persönlichen Bezie-
hungen. Da stabile persönliche Beziehungen die Rehabilitation und Adaptation an 
chronische Erkrankungen fördern, ist davon auszugehen, dass eine gesteigerte 
Vergebungsfähigkeit dem Krankheitsverlauf von FMS Patienten zuträglich wäre.   
Frühere Studien konnten zeigen, dass Ärger, insbesondere jener, der nach innen 
gerichtet ist, zu einer Verstärkung von vorbestehenden Schmerzen und zur Ver-
schlechterung einer Depression führen kann. Zudem stellte sich heraus, dass Ver-
gebung einen abschwächenden Effekt auf den Ausdruck von Ärger haben kann 
und überdies dazu neigt, die Selbstkontrolle über den Ärger zu stärken. Folglich 
könnte eine auf Vergebung basierende Intervention vielversprechend sein, die den 
Fokus darauflegt, den nach innen gerichteten Ärger zu reduzieren und zugleich 
Ärger auf eine gesunde Weise auszudrücken in den Mittelpunkt stellt.  
In der Literatur wurde zudem eine Verbindung von Ärger-Rumination und Symp-
tomschwere beschrieben. In Konkordanz mit früheren Studien zeigen unsere Er-
gebnisse eine inverse Korrelation von Vergebung mit Ärger-Rumination, weshalb 
FMS Patienten auch hier von einer Vergebungsintervention profitieren könnten.  
Wir halten weitere Forschung in diesem Bereich sinnvoll. So könnte beispielsweise 
eine Longitudinalstudie, in welcher im Rahmen einer Vergebungsintervention Är-
ger- und Stresslevels untersucht werden, zu einem besseren Verständnis führen 
wie FMS, Vergebung, Ärger und Stress miteinander verknüpft sind. Dies wäre der 





This dissertation is intended to help further the understanding of a disease that is 
too often overlooked and sometimes even denied of its existence. Millions of 
people struggle worldwide with debilitating symptoms yet there is widespread 
misunderstanding among health care professionals that Fibromyalgia is just “all in 
the head”. Ironically, unrelenting attention is paid to other medical conditions that 
are clearly “all in the head”, such as strokes or brain tumors. Fibromyalgia, 
however, has long been obscured from the eye of mainstream medicine. This is 
because some of its aspects overlap with the field of psychology. Adherence to the 
Cartesian model of mind-body dualism has resulted in a lack of interest in the 
psychological side of physical conditions and deemed diseases without 
immediately quantifiable correlate illegitimate. The Hippocratic Oath, the ancient 
principle of medical conduct, calls to “[…] use treatment to help the sick according 
to [one´s] ability […]”. It is not for us physicians to decide if an ailment is real but 
to do everything we can to try healing it.  
The causes of Fibromyalgia have been debated, some say it is an abusive parent, 
functional HPA-axis aberration or simply behavioral rigidity. In a conversation with 
Fibromyalgia patients, though, one will find out that to them none of that matters 
because they only want one thing: A remedy. However, neither a remedy nor 
means for sufficient long-term symptom improvement have been discovered to this 
day. As part of an international effort to develop an effective FMS treatment, this 
work deals with psychological concepts that are relevant to FMS formation and 












2. Problem discussion 
2.1. Fibromyalgia syndrome 
2.1.1. Definition, prevalence and symptomatology 
Fibromyalgia Syndrome (FMS) is a chronic pain disorder that causes multifocal 
pain and sensitivity to touch, along with other symptoms. It affects over two percent 
of the population, mostly women (1). 
The majority of the pain loci are located in the musculoskeletal system, but they 
are usually accompanied by pain in other body areas. The classification criteria 
established in 1990 by the American College of Rheumatology (ACR) define FMS 
as tenderness to touch in at least 11 of 18 specified sites (tender points) and 
chronic widespread pain (CWP) (2). CWP is defined as at least three months of 
persisting axial pain, left and right sided pain and upper and lower segment pain. 
The ACR also defines other not pain related conditions as core symptoms of FMS, 
including sleeping problems and cognitive impairment. Patients with FMS report 
waking up unrefreshed, fatigue (3) as well as memory and thought problems (4). 
Also, morning stiffness, problems concentrating, depression, anxiety and even 
vegetative symptoms like gastroesophageal reflux disease and irritable bowel 
syndrome have been documented. 
The economic burden Fibromyalgia has on society is high. Patients use 
significantly more health care resources than healthy individuals. They seek help 
from physicians more often and have a higher consumption of pain medication. 
The disease also interferes with their employment, as patients have significantly 




FMS is classified a functional somatic syndrome. Functional somatic syndromes 
are identified as a clinical complex of bodily symptoms which cannot be explained 
by a somatic factor (e.g. structural tissue damage, biochemical disorder, specific 




FMS has a relevant overlap with anxiety disorders and depression. Weir et al. 
found that FMS patients were 2,1 to 7,0 times more likely to suffer from comorbid 
depression compared to the non-FMS population (7).  
While some of the symptoms (fatigue, pain) of a Major Depression Disorder can 
be congruent with FMS, not all FMS patients are depressed. Also, pain locations 




Even though the ACR´s criteria of 1990 for FMS were designed to classify, not 
diagnose the disease, they have become the main diagnostic tool in practice and 
study. However, the concept of using tender points has been criticized because of 
its lack of approval by non-rheumatologists. Also, 
its insufficient objectivity, missing data concerning 
its reliability outside the rheumatologic setting as 
well as poor validity have been disputed  (8,9). 
Therefore, the criteria of 1990 were reviewed and 
modified by the ACR resulting in the establishment 
of the new, though preliminary, diagnostic criteria of 
2010. The symptom triad of chronic pain in various 
areas of the body, fatigue and sleeping disorder are 
now determined to be the core criteria for the 
diagnosis of FMS. Also, the doctor´s estimate of the 
symptoms´ effect on the body has been replaced 
by a questionnaire in which the patient self-
assesses his or her condition.  
The so-called New Clinical Fibromyalgia 
Diagnostic Criteria questionnaire contains two 
parts. In the first, which is designed to measure the Widespread Pain Index (WPI), 
the patient checks each area that they have felt pain in over the past week. The 
respective WPI is calculated by adding all body parts checked, with a maximum 
Image: Body regions of the            




score of 20. The second part contains the Symptom Severity Score (SS-Score) in 
which the patient indicates their fatigue, waking unrefreshed and cognitive 
symptoms, each on a scale from 0 to 3. Then the patient checks other symptoms 
on a list of 41 other possible symptoms. For each 10 symptoms checked, the 
patient accumulates an additional point (up to 3 possible). The points of each sub-
scale are then added together. Eventually, the diagnostic criteria for FMS are met 
if the patient scores >7 in the WPI and >5 in the combined Symptom Severity 
Score.  
Along with completing the New Clinical Fibromyalgia Diagnostic Criteria 
questionnaire, the doctor is advised to explore specifically the patient’s fatigue and 
sleeping problems. The patient´s history must be taken and a complete body 
examination must be performed. Also, a full blood count, including blood 
sedimentation, CRP, Creatine Kinase, Calcium and TSH must be determined to 
rule out other possible causes. If the results hint towards a different disease, further 
investigation becomes necessary (10). 
There is an abundance of differential diagnoses for chronic multilocular pain. 
Hormonal (e.g. inflammatory rheumatic diseases, various tumors, osteoporosis, 
hyper-/hypoparathyroidism, hyper-/hypothyroidism) and metabolic (e.g. Vit. D. 
insufficiency) causes and substance abuse (e.g. heroin, cocaine) are just a few. 
Also, neurological diseases and prescribed medication side effects can cause 
similar symptoms. 
About 10-15% of the patients taking statins present with myalgia of different 
severity. Arthralgia and myalgia can be side effects of interferon (11) and 
aromatase inhibitor therapy (11). 
 
 
2.1.4. Levels of severity 
According to several clinical characteristics there are different levels of severity 
though a generally accepted classification of severity is not available. The 




German AWMF differentiates between the mild and severe (10). The transition 
between the two is smooth.  
The mild form presents with mainly musculoskeletal pain with recurring low pain or 
pain free episodes. The patient´s psyche is only mildly affected; the psychosocial 
background remains mainly intact. The patient himself is usually cooperative. 
The severe form is characterized by a number of symptoms including 
musculoskeletal pain and symptoms referring to other organ systems. The pain is 
continuous, pain free intervals are rare or nonexistent. Psychosocial stressors like 
family and work are numerous and severe; altogether the psychic ramifications of 
the disorder are high.  
 
 
2.1.5. Etiology and risk factors 
At this time, no conclusive results concerning the etiology have been published. 
Researchers assume that there is a number of potential risk factors for the genesis 
of FMS and CWP. 
The following biological, mechanic and psychosocial factors can be associated 
with the development of FMS: 
 
Table 1: Factors associated with FMS development 
Biological - Genetic Polymorphisms: beta2 adrenergic Receptors, ACTH   
Precursor Receptor, corticosteroid–binding globuline 
- Dysfunction of the hypothalamic-pituitary-adrenal axis    
Mechanic - forced posture/movement (kneeling at work, repetitive   
movements of wrists) 
Psychological 
distress 
- low body related health quality 
- sleeping disorders 
- persistent live threatening events 
- hospitalization after traffic accident 
- childhood spent in an orphanage 
- maternal death 
- financial woes 





FMS often occurs in two or more members of the same family. Family studies 
indicate that first degree relatives of FMS patients have an eight-fold risk of 
developing the disorder as compared to families with rheumatic arthritis (14). 
The role of infections as a precipitating or aggravating factor is being discussed. 
For example, a relationship of the genesis of FMS and chronic Hepatitis C has 
been postulated, but due to inconclusive research this possible cause remains 
contested. Also, a link to Lyme disease which presents with symptoms similar to 
FMS (musculoskeletal pain, fatigue, concentration deficits) is being investigated. 
In a study conducted at a university hospital of 287 patients suffering from Lyme 
disease 22 developed FMS. Antibiotic therapy alleviated the Lyme related 




There are numerous studies attempting to define the pathogenesis of FMS, but 
most remain contested due to the heterogeneity of the disorder. Only few factors 
are believed to be linked to FMS pathogenesis; these include 1. alterations of 
central processing of sensory input, 2. neuroendocrine abnormalities, 3. peripheral 
pain generators. 
 
1. There is some evidence that FMS patients process pain abnormally. A study 
conducted by Gracely and colleagues tried to elucidate this mechanism. 
Moderate pain was applied through pressure on the left thumbnail of FMS 
patients and controls while undergoing fMRI. Evaluating the increase of 
cerebral regional blood as an indicator of cerebral activation, the 
researchers concluded that approximately 50% less stimulus intensity is 
needed to evoke a pain response in FMS patients, compared to a healthy 
control group (16). These findings suggest that the lower pain threshold 
typical in FMS patients may be associated with a modification of input 





2. Aberrations of the hypothalamic-pituitary-adrenal axis have been 
postulated. McCain and Tilbe showed that plasma cortisol in FMS patients 
is overall significantly higher, compared to patients with rheumatic arthritis. 
FMS patients also displayed higher peak and basal cortisol levels (18). 
Those findings make an inability to suppress cortisol likely. Other studies 
have also focused on cortisol levels in FMS patients. Harris and colleagues 
observed no relationship between cortisol level and stress symptoms as 
they measured salivary cortisol levels at five time points a day on two 
consecutive days. In women with FMS, however, a relationship of cortisol 
and early day pain symptoms could be established (19). 
3. Peripheral Pain Generators may contribute in the emergence or upkeep of 
FMS (20). In 2008, Caro and Colleagues published a study trying to 
substantiate the hypothesis that an immune modulated disease could be 
causative for FMS. Among other subjective and objective measurements, 
they use electro diagnostics to illustrate demyelination and polyneuropathy. 
In one third of the FMS patients, the findings demonstrated a distal 
demyelinating polyneuropathy possibly on the grounds of a chronic 
inflammatory demyelinating neuropathy (21). 
 
 
2.1.7. Management and therapy 
Given the versatility of the disorder, only very few therapies offer sufficient 
symptom alleviation. It has become evident that the approach should ideally be 
polytherapeutic rather than focusing on one concept only.  
When choosing the right therapy, possible co-morbidities (e.g. depression, 
arthrosis) must be considered, tested for and treated separately. 
 
 
2.1.7.1. Recognizing the disease 
The first step to help the patient is to inform him or her of the diagnosis. Matching 




a patient who has often undergone countless medical examinations and frustrating 
therapeutic efforts. In a Canadian study, patients reported being more content with 
their condition and suffering less from FMS symptoms 18 months after their 
diagnosis (22). Also, the patient should be made aware of the legitimacy of their 
disorder. Patients with FMS often feel neglected and not taken serious by their 
social group. Establishing the realness of the suffering can help to bridge the divide 
that Fibromyalgia has created between the patient and their environment. Now the 
patient has medical proof that his or her pain is not “just in the head” and that their 
suffering is both real and legitimate. Often this is, too, a relief for the patient’s family 
and friends. They are reassured that their family member or friend is not crazy but 
struggling and in need of their support. 
However, the patient should be informed that the condition cannot be confirmed by 
laboratory testing because it is not caused by structural changes in the body. The 
implications of psychophysiological relationships should be explained to the 
patient in order to extend the patient´s understanding of how and why the disease 
occurred. Fear and uncertainty should be lessened by assuring the patient that the 
life span is typically not reduced by Fibromyalgia (23). 
 
 
2.1.7.2. Physiotherapy, occupational therapy and physical therapy 
The FMS guideline commission reviewed preexisting research of physiotherapy, 
occupational therapy and physical therapy and their respective short and long-term 
efficacy, as well as tolerability and safety. They only included studies in which 
examinees received therapy for more than 20 weeks. They recommended cardio 
workouts of low and medium intensity such as walking, riding a bicycle, dancing 
and aqua jogging with thrice weekly practice sessions of 30 minutes and more. 
The studies reviewed showed a beneficial effect on FMS patients´ pain and life 
quality. Functional training, such as water gymnastics, a combination of aerobic 
training, stretching, strength and coordination, as well as similar procedures of low 
and medium intensity outside the water, showed positive results when performed 




therapeutic approaches such as hydrotherapy (swimming in water of high 
temperature or high mineral content), vibration exercise, bio sauna, infra-red 
therapy should be discussed individually according to the authors.  
Physiotherapy was deemed a useful element of a multimodal therapeutic concept. 
The studies reviewed showed that physiotherapy could help loosen aching and 
cramped muscles, as well as increase the endurance, mobility and stability of FMS 
patients.  
Occupational therapy was recommended in particular where FMS symptoms 
interfere with a patient´s ability to work or care for him or herself. That is achieved 
through a number of different ways such as the development of beneficial daily 
routines, coping strategies and quality of life enhancement exercises (24).  
 
 
2.1.7.3. Complementary and alternative therapy 
Langhorst et al. published an overview of systematic review guidelines as part of 
the updated guidelines on complementary and alternative therapy of FMS. They 
compiled recent articles and recommendations by 13 scientific societies as well as 
two self-help groups on the effectiveness, tolerability and risk of procedures such 
as manual acupuncture, electro acupuncture, Qigong, Tai-Chi, Ai-Chi and Yoga. 
The data showed that meditative movement therapy such as Qigong, Tai-Chi and 
Yoga had positive effects on the well-being of FMS-patients while acupuncture was 




The German guidelines recommend psychotherapy for FMS patients who show 
maladaptive disease management strategies (such as catastrophizing, insufficient 
perseverance or inappropriate avoidance). It has also proven useful for patients 
with relevant interference by psychosocial stressors and patients with comorbid 




cedures and their effectiveness in the FMS setting, Köllner et al. examined mind-
fulness-based stress reduction, biofeedback, relaxation routines, Hypnosis and 
guided imagination, cognitive behavioral approaches and therapeutic writing. They 
concluded that especially cognitive behavioral therapy yielded good results and 
was to be recommended for the treatment of FMS. However, the studies sug-
gested that biofeedback and hypnosis/guided imagination had no significant im-
pact on pain, sleep quality and quality of life and was therefore a therapeutic mo-
dality that should be discussed individually. The authors advised against mono-
therapeutic mindfulness-based stress reduction techniques, relaxation routines 
and therapeutic writing (26). 
 
 
2.1.7.5. Multimodal therapy 
Schiltenwolf et al. reviewed articles on the short- and long-term efficacy, tolerability, 
safety and the components necessary for multimodal therapy of FMS patients. 
They included studies on multimodal therapy that combined at least one activating 
element (such as aerobic training) with at least one psychological intervention. 
Their cumulative study analysis showed that multimodal treatment sessions of 
24hrs and more had a positive effect on pain, sleeping problems, fatigue and life 
quality and thus recommended multimodal therapy for patients with severe FMS 
symptom expression. Moreover, their analysis showed medium- and long-term 
efficacy within the in- and outpatient setting (27). 
 
 
2.1.7.6. Drug-based therapy 
The updated German guidelines of 2017 state that drug therapy of FMS is not 
compulsory. They advise that pros and cons should be thoroughly discussed with 
the patient. Personal preference, experience and comorbidities should also be 
taken into account. When both patient and physician conclude that drug-based 
treatment is necessary, tricyclic antidepressants such as amitriptyline can be used 




Drugs have proven especially useful in short term settings, reducing pain and 
sleeping problems. Fluoxetine and paroxetine, selective serotonin reuptake 
inhibitors that increase serotonin levels in the synaptic gap have shown to be as 
effective as amitriptyline (28).  
Duloxetine, an SSNRI which increases serotonin and noradrenaline in the synaptic 
gap, has proven to reduce pain in FMS patients both with and without comorbid 
major depression.  
Moreover, pregabaline and quetiapine, antiepileptic drugs which can also be used 
against neuropathic pain, have proven useful. Studies investigating their efficacy 
have concluded that pain reduction as well as improved sleep and health related 
quality of life are possible under pregabalin therapy (29,30). In their literature 
review, Sommer et al. advise against the use of non-steroidal anti-inflammatory 
drugs and opioids.  
 
Table 2: Pharmacological FMS - treatment 
Drug Recommendations of the Guidelines by the "German      Society of Pain", 2017 (31) 
Amitriptyline temporary off-label use of amitriptyline (10-50mg/day) is ad-vised  
Duloxetine 
temporary off-label use of duloxetine (60mg/day) is advised 
when patients suffer from comorbid major depression and 
generalized panic disorder and Amitriptyline is not tolerated 
Pregabaline 
temporary off-label use of duloxetine (150-450mg/day) is 
advised when patients suffer from comorbid generalized 
panic disorder when Amitriptyline is not tolerated.  
Quetiapine 
temporary off-label use of quetiapine (50-300mg/day) can 
be discussed when patients suffer from comorbid major de-







temporary off-label use of fluoxetine and paroxetine (both 
20-40mg/day) can be discussed when patients suffer from 
comorbid depression or anxiety disorder. 
 
Because no drug has been specifically approved for FMS treatment in Germany, 
risks of drug treatment should be diligently conveyed to the patients and consent 
should be documented in order to avert legal issues.  
 
 
2.2. Forgiveness, anger and anger rumination 
As previously mentioned, Fibromyalgia is a disease with a strong psychological 
component. In order to establish a better understanding of the disease, various 
relevant psychological concepts have been scrutinized (e.g. depression (32), self-
esteem (33), emotional processing and somatic attribution (34)). As many FMS 
patients struggle with maladapted emotion regulation caused by negative 
experiences of the past, they often experience high levels of anger and anger 
rumination (35,36). In this study, we decided to focus on the construct of 
forgiveness as a positive coping mechanism and how the ability to forgive relates 





The first personality construct discussed in this study is forgiveness. Forgiveness 
as a core component of human well-being has been mostly neglected by the 
medical and psychological field until researchers discovered the malevolent effects 
of its absence and its positive capacities to resolve conflict. One of the reasons for 
its late discovery lies in the fact that the health sciences draw their knowledge 
traditionally from natural sciences. Forgiveness, with its ethnic and religious 
charge, its sociocultural complexity and the intricacy to depict it empirically, has 




Classic psychologists like Freud, Adler and Frankel contributed nothing or only 
very little on the topic. Among the first forgiveness researchers were Piaget and 
Behn, American psychologists who proposed that forgiving evolved from a high 
degree of morality (37). The German psychologist Fritz Heider also linked 
forgiveness in the 1930s to upholding ethical standards by the victim of a conflict.   
It was not until the 1980s that forgiveness received widespread attention when its 
relevance in the fields of developmental, clinical and social psychology were 
discovered (37). Consecutively, forgiveness was gaining momentum within the 
field of chronic pain (e.g.(38)). 
Today, as with many psychological concepts, the definition of forgiveness is 
disputed. Toussaint defines it as a multidimensional phenomenon which describes 
the intentional letting go of a person´s negative thoughts, feelings and actions 
towards someone who committed a wrong against them (39). It has also been 
described as the counteracting of the desire to avenge oneself. Forgiving someone 
does not only imply the emotional betterment of the transgressed but is a prosocial 
act of reaching out to the transgressor for the sake of both individuals´ well-being. 
Forgiveness not only promotes subjective well-being but has also been found to 




2.2.1.2. Forgiveness of others 
Forgiveness of others becomes relevant in the context of an action performed 
against an individual which they view immoral, unjust or noxious (41). 
This action typically evokes emotional reactions such as fear or anger in the victim 
and guilt in the perpetrator. These emotional reactions can result in motivational 
consequences. For example, the victim might express the desire to exact revenge 
upon the transgressor, while the transgressor might try to avoid the victim. Also, 
cognitive reactions are likely. Hostility on the one side and denial on the other can 
be two of them (41). These coping mechanisms can be the cause for continuous 




employed by the victim to maneuver out of emotional upheaval and implies 





Self-forgiveness is the process of forgiving oneself. It occurs in forgiveness 
scenarios in which an individual has caused harm on another individual or on 
themselves. The degree of severity can reach from relatively mundane 
transgressions, like missing a diet goal or watching too much TV, to serious actions 
like inflicting physical harm on family members. Self-forgiveness is difficult to 
achieve because transgressors often deny accountability for their actions or see 
their competence to self-forgive hindered by the lack of forgiveness from the 
transgressed (43).  
Several studies have highlighted the importance of self-forgiveness on mental 
health. Research has demonstrated a link between the lack of self-forgiveness and 
its relationship with anxiety and depression. For example, Ross et al. established 
a link between low rates of self-forgiveness and a style negative of self-reflection, 
including feelings of guilt, worthlessness (44).  
The positive correlation of forgiveness seems to extend beyond mental health to 
physical health as well. In a sample of over 5000 examinees, Don Davis et al. 




2.2.1.4. Forgiveness in patients with FMS 
The implications of forgiveness in the pathogenesis of psychological and 
psychosomatic ailments have been the scope of a few conceptual studies. The 
state of unforgiveness is considered a core component of unhealthy interpersonal 
conflict management. This results in ongoing, high levels of stress which, in turn, 




influence of forgiveness on chronic pain, myalgic encephalomyelitis (chronic 
fatigue syndrome) (39) and Fibromyalgia Syndrome has been suggested.  
Research on FMS has shown that patients often struggle with high levels of stress 
caused by everyday life situations which often involve interpersonal conflict (47). 
Also, intrapersonal conflict, e.g. not being able to fulfill one´s own expectations, 
have been identified as a relevant source of stress in FMS patients. In addition, 
stress and the physiological activation it encompasses have shown to deteriorate 
FMS symptoms (48). Ergo forgiveness, as a benevolent means to overcome 
conflict with other human beings as well as with oneself, has been theorized to 
effectively reduce psychosocial stressors and therefore FMS symptom expression. 
Nonetheless, literature on the outcome of forgiveness interventions on patients 





According to Charles Darwin (1872) anger is a mechanism used by “animals of all 
kinds, and their progenitors before them, when attacked or threatened by an 
enemy, to fight and protect themselves”. C.D. Spielberger defined it as an 
“emotional state of feeling that varies in intensity, from mild irritation to fury and 
rage” (49). In a survey conducted by Kasinove et al. across Russia and the United 
States, interviewees stated that they experienced anger more than once a week 
and it was typically evoked by a person close to them. Gender specific differences 
were detected as men were more likely to direct their anger outwards, towards 
another person or an object (50). In other words, men would show a greater 
inclination to be physically aggressive when angry compared to women.  
Internal and external triggers of anger are being discussed. An external trigger is 
a momentary, situational source of anger that arises from an external source. For 
example, this may occur when one is cut off in traffic. Internal triggers include 




evaluation and negative connotations are commonly attributed to the situation (e.g. 
unfairness) or the originator (e.g. blameworthiness, intentionality) (52). 
Simultaneously, the whole body finds itself in a state of increased activation 
moderated by a boosted sympathetic nervous system. Thus, anger is considered 
a psychobiological feeling causative for emotional and bodily stress.  
The implications of anger in psychosomatic and somatic disorders have been 
investigated extensively. Janice Williams of the American Heart Association 
conducted a study (n=12,986) in 2000 examining prospectively the association 
between trait anger and the risk of suffering from coronary heart disease (CHD). 
Normotensive women and men exhibiting high levels of trait anger were placed at 
significant risk for atherosclerosis induced CHD morbidity and even death (53). 
 
 
2.2.2.2. Anger subcategories 
According C.D. Spielberger, a prominent researcher in the field of anger whose 
anger measuring instruments were used in this study, anger can be specified into 
the following subgroups (53,54): 
Anger-in: Anger – in is synonymous with anger inhibition and has been 
 described as the tendency to suppress anger and aggressive impulses. 
Anger-out: Anger out is considered a person´s propensity to direct anger  
 externally either towards persons or objects.  
State anger: State anger is the momentary state of being angry in a situation 
 eliciting feelings such as annoyance, irritation or rage. 
Trait anger: While State anger is temporary, Trait anger is considered a           
predispositional quality that predicts the  frequency, intensity and duration 
of anger episodes. People with high levels of trait anger experience anger 
and fury more often, more intensively and longer lasting compared to people 




2.2.2.3. Anger and FMS 
The maladaptive effect of anger can influence the daily life as well as symptom 
expression in FMS patients greatly (35). 
Often months or even years pass until the disorder is diagnosed correctly. The 
symptoms associated with FMS are often not considered real or legitimate. 
Because of the lack of visible manifestations and no conclusive findings in 
elementary lab workup, both the social group and many health care professionals 
often denounce them as “all in the head”. Until the right diagnosis is made, patients 
often suffer from immense pain and fatigue. The combination of experiencing 
ongoing agony and the lack of recognition thereof can result in strong feelings of 
anger and helplessness.  
Sayar and colleagues investigated the relationship between anger and 
Fibromyalgia symptoms. Fifty FMS patients were compared with 20 subjects with 
Rheumatoid Arthritis and 42 healthy controls. After the subjects completed multiple 
questionnaires, including the state trait anger inventory and the Fibromyalgia 
impact questionnaire, the researchers found that anger – in was significantly higher 
in patients with FMS compared to the RA controls. They also found that anger – 
out scores and anxiety scores correlated with pain perception. Altogether they 
postulated that the behavioral expression of anger, combined with anxiety, can 
predict pain intensity in FMS patients (55).  
Moreover, anger may trigger pain induced physiological reactivity and muscle 
tension and therefore might be a key variable to overall symptom intensity in 
patients with FMS (56).  
But anger can also have positive effects. A diary study was conducted in which 
several hundred female FMS patients were asked to daily record their state anger 
inhibition (anger in) and their anger expression (anger-out) following one 
emotionally charged event of the day. At night, they were asked to specify their 
end-of-day pain. Van Middendorp and his colleagues concluded that FMS patients 
with a proneness to express anger experienced lower symptom severity than 




described people with a propensity to internalize anger as “pain prone patients” 
(57). The analgesic quality of open anger expression was particularly effective in 
patients with high trait anger (35). At the same time, expressing anger in 




2.2.3. Anger rumination 
2.2.3.1. Definition 
Rumination has been described as recurring thoughts that revolve around a 
negative experience, evoking a state of emotional distress (59). After an event in 
which the sentiment of anger was evoked, an individual might experience recurring 
thoughts revolving around anger-evoking event. These can occur without 
situational demand shortly and long after the initial provocation. Sukhodolsky 
described the term anger rumination as the following: “If anger is viewed as an 
emotion, anger rumination can be defined as thinking about this emotion” (51). 
Triggers of anger rumination can be found both internally and externally. An internal 
trigger is a negative memory, e.g. “This reminds me of how badly my ex-wife used 
to treat me”, which incites angry affect. An external trigger, on the other hand, is 
considered a cause for anger that originates outside the individual, for example, 
rude behavior by fellow human beings.  
Sukhodolsky established four different anger rumination subcategories: angry 
afterthoughts, angry memories, thoughts of revenge and understanding of causes 
(51). Angry afterthoughts pertain to anger eliciting events of the recent past, such 
as being cut off in traffic. The subcategory, angry memories, involves thinking 
angrily about an experience of the distant past, such as being treated unfairly by 
an educator in childhood. The subcategories, thoughts of revenge and 
understanding of causes, represent the act of counterfactual thinking which 




actually did. Thoughts of revenge includes cognitive approaches to become 
actively involved to resolve the conflict. The subcategory understanding of causes 
involves investigating the problem´s root and thus achieving a grasp on how the 
anger come about.  
Studies have established the detrimental effects of anger rumination including its 
link to depression, high levels of anger, sympathetic arousal and aggressive 
behavior (60). A link to other chronic illnesses has been described in a few studies. 
Laing et al. found a strong association of anger rumination and low quality of life in 
patients with multiple sclerosis (61). Moreover, anger rumination was associated 
with coronary artery stenosis in an Iranian sample of 200 (62).  
 
 
2.2.3.2. Anger rumination and FMS 
To our knowledge, anger rumination in patients with FMS has not been 
investigated specifically, even though research on anger and rumination in FMS 
patients is available. Rumination in FMS patients has been hypothesized to 
influence psychological variables like mood, control, optimism and others which, 
in turn, correlate with stress levels (63). The reason why anger rumination research 
in FMS patients is particularly interesting is because preexisting research indicates 
high levels of anger and self-focused reflection in patients with FMS (64). This begs 
the question if there is a difference in how FMS patients deal with their anger 
compared to healthy individuals. Is their ruminative thought process revolving 
around recent or more distant events (which could maybe be related to the 
biographical calamity which is experienced by many FMS patients)? Overall, 
research on anger rumination could lead to a better understanding of the anger 








2.3. The concept of stress 
Because unforgiveness, anger and anger rumination ultimately result in 
psychological and physiological stress, this chapter serves as an overview on the 
concept of stress. It also deals with its general health implications and underlying 
physiological principles. Moreover, it outlines the role of stress in pain generation 




The surge of stress related diseases in our modern world has helped stress gain 
momentum in clinical research. Richard Lazarus, one of the main protagonist of 
incipient stress research, described it in 1966 as something that “arises when 
individuals perceive that they cannot adequately cope with the demands being 
made on them or with threats to their well-being” (65), a definition that most 
scholars agree with. 
Stressors are ubiquitous: Psychosocial stressors range from social (e.g. 
interpersonal conflict, moving, finances) to workplace related (e.g. working long 
hours, work over/underload, public speeches) to health related (e.g. chronic 
disease or injury, chronic pain, or the fear thereof). 
There are two interconnected neurological systems that control the physiological 
stress process. Those are the locus coeruleus-norepinephrin (LC-NE) axis and the 
hypothalamus-pituitary-adrenal (HPA) axis. They are controlled by the corticotropin 
releasing factor (CRF) produced by the hypothalamus and secreted when 
superordinate brain structures like the amygdala, hypothalamus and others 
demand it. The LC-NE axis typically becomes active in situations of immediate 
stress resulting in a fight-or-flight response of the body that was phylogenetically 
designed to survive life or death situations. Conversely, the HPA axis is intended 
to prepare the body for long term stress. It is activated by situations which require 
perseverance or in situations in which a loss of control is perceived. Both systems 




defend. These include the cardiovascular system and katabolic metabolism and 
power down energy spenders like the reproductive, the digestive and the immune 
system (48). Overpowering doses of stress eventually lead to poor health. 
Evidence is growing that stress can be causative of upper respiratory infections, 
such as asthma, herpes, infections and delayed wound healing. But even links to 
the great killers of our time, including cardiovascular disease, stroke and HIV/AIDS 
could be attested  (66). While stress is a natural component of life, the inadequate 
activation of the sympathetic nervous system is believed to have detrimental 
effects. Studies on both humans and animals have shown that this inadequacy of 
the stress response can be caused by early life trauma which results in HPA axis 
malfunction. The deficiency leads to increased stress vulnerability later in life (67).  
 
 
2.3.2. The physiology of the stress/pain relationship 
When psychological (e.g. workplace related) and biological (e.g. inflammation) 
stressors stimulate the endogenous stress system, the secretion of various stress 
hormones like corticotropin-releasing factor (CRF), cortisol, catecholamines and 
others is triggered. However, research on the stress – pain relationship has shown 
that those stress hormones can have both analgesic and pain-amplifying features 
depending on which stress axis is set off. Acute stress situations, followed by NC-
LE axis stimulation, lead to hypoalgesia, whereas chronic stress can have 
hyperalgetic effects via HPA axis activation. The mediator in both cases is believed 
to be CRF (68). Studies in which CRF was administered to non-human primates 
indicated that CRF not only serves as the HPA´s primordial trigger but that CRF 
itself acts as a neurohormone which induces physiological and behavioral arousal 
via the activation of the sympathetic nervous system (69). Growing evidence also 
suggests that stressors can induce the secretion of neuroinflammatory cytokines, 
such as interleukin-1β, interleukin-6 and tumor necrosis factor-α, which foster 





2.3.3. Stress and FMS 
The relationship between stress and FMS has been the scope of several studies. 
Investigators have established high levels of both psychological as well as 
physiological stress in patients with FMS. These are caused by negative life 
experiences as well as by daily personal struggles (71).  
Studies trying to identify common stressors in patients suffering from Fibromyalgia 
have demonstrated that FMS patients have a higher probability of sexual 
victimization compared to non-FMS individuals (72). Boisset-Pioto showed that in 
a sample of 161 females, patients with FMS had a much higher lifetime prevalence 
(17%) than non-FMS individuals (6%) (73). Moreover, the burden of FMS-related 
symptoms seems to be significantly higher in FMS patients subjected to sexual 
abuse (72). 
It seems likely that a dysregulation of the autonomous response to these stressors 
is at least partly responsible for the pain. It has proven difficult, though, to designate 
the exact mechanism of malfunction. Patients with FMS have shown normal basal 
cortisol secretion yet a delayed ACTH plasma peak upon IL-6 stimulation (74). This 
indicates that even though basal plasma cortisol is within the normal range, cortisol 
secretion in stressful situations is hampered by reduced HPA activity (75).  
Symptomatic approaches intended to alleviate pain and other symptoms in FMS 
patients have shown short term efficacy by directly or indirectly addressing the HPA 
axis. These include physical exercise, tricyclic antidepressants and serotonin 
reuptake inhibitors (68). Also, symptom reduction through psychological 
interventions which focus on stress reduction have proven efficacious. Among 
those interventions are meditation, cognitive therapy and biofeedback (76).  
As psychoemotional concepts like guilt, shame and blame are increasingly stud-
ied, they have also been scrutinized as mediators of the Fibromyalgia and stress 
relationship. For example, Gustavson et al were able to show stress reduction in 
FMS patients through the self-empowering rehabilitative approach “from shame 





3. Study objectives and hypotheses 
With this study, we want to explore whether patients with FMS show signs of 
maladapted emotion regulation resulting in elevated levels of anger and anger 
rumination. Because forgiving is a promising coping mechanism and can avoid 
detrimental levels of angry emotions, we want to take a closer look on how 
forgiveness relates with anger and angry rumination.  
 
Hypothesis 1: Patients with FMS have lower levels of forgiveness than 
healthy controls measured by the Mauger forgiveness of self and others 
scale (40).  
Hypothesis 2: FMS patients show higher levels of anger than health 
controls. Anger is measured by the state trait anger expression inventory 
(78). 
Hypothesis 3: Patients with FMS ruminate more than healthy controls. 
Rumination is measured by the anger rumination scale (51). 
 
We want to detect possible correlations between forgiveness, anger and 
rumination and the health status of patients with FMS. In order to elucidate those, 
we correlate the results of the Mauger scales, the STAXI and the ARS to the 
disease specific health status instrument Fibromyalgia impact questionnaire (FIQ) 
(79) to anxiety and depression measured by the hospital anxiety and depression 
scale (HADS) (80) and quality of life measured by the short-form 12 (SF-12) (81) 
and the quality of life scale (QOLS) (82).  
 
Hypothesis 4: Forgiveness correlates positively with better FMS specific 
health status, less anxiety, less depression and better quality of life.  
Hypothesis 5: Anger and anger rumination correlate with lower FMS 






4.1. Study design 
In this cross-sectional study, patients with FMS were compared with healthy 
controls using a paper-based, self-administered questionnaire battery. 
Objective and design were in accordance with the ethical principles established 
within the Declaration of Helsinki. The study was approved by the ethics committee 
of the Ludwig Maximilian University in Munich, Germany (Studienprojektnummer 
103-13). 
The questionnaire battery contained several questionnaires assessing the 
examinee´s sociodemographic data as well as pain scales, the Fibromyalgia 
impact questionnaire, the quality of life scale, the short form health survey 12, 
hospital anxiety and depression scale, Mauger forgiveness of self and others, 
state trait anger expression inventory and the anger rumination scale. !
 
 
4.2. Data collection 
Between May 2013 and August 2014, a total of 320 questionnaire batteries along 
with an information letter and a consent form were delivered to several German 
Fibromyalgia support groups across Germany who had agreed to participate in the 
study. Among the self-help groups which responded to our inquiry was “Deutsche 
Fibromyalgievereinigung” with about 4800 members at the time. 
The group instructors were contacted and were then sent the materials including 
the questionnaires, an information letter regarding the study objectives, and a 
consent form. Group leaders were asked to distribute the materials and to collect 
and return them upon completion. A total of 173 FMS patients (response rate = 
54%) filled out the set. Post-hoc power calculation was determined with a required 
minimum power of 0.8. Additionally, as two main outcomes were considered 
(forgiveness of self, forgiveness of others), alpha was reduced using Bonferroni 
correction and resulting in 0,025. The smaller occurring difference was considered 




Pain-free controls (N = 81) were a German convenience sample of volunteers 
without FM that completed the questionnaire set. Controls were recruited using 
similar snowball sampling methods to reach individuals of a variety of ages. Initial 




4.3. Study population 
The Fibromyalgia support groups (e.g. Deutsche Fibromyalgievereinigung) 
distributed the material autonomously among their members. Of 320 delivered 
sets, 173 completed questionnaires were returned to us (response rate = 54%). 
Our controls (N = 81) received the same material. They were recruited with the 
help of Prof. Niko Kohls at the University of applied Sciences of Coburg using a 
snowball sampling method. Initially, the surveys were handed out to students who 
passed them on to their parents, grandparents, friends of their parents and their 
immediate social group. Thus, people of all ages were targeted.  
Inclusion criteria were: 
– Age between 18 and 75 
– Willingness to participate 
– Ability to understand the consent form and consent 
– Sufficient comprehension of the German language 
– (only patients) FMS diagnosis 
– Signed informed consent 
 
Exclusion criteria were 









4.4. Scales and questionnaires 
4.4.1. Sociodemographics 
The first few general questions inquire about the subject´s age, gender, religion, 
marital status and educational status. Then the subject is asked to estimate their 




4.4.2. Pain scales 
In the second part facts pertaining to the individual patient history, pain intensity 
and pain localization were collected. The questions contain pain duration, date of 
the diagnosis of FMS, today´s pain intensity and pain frequency of the past three 
months by rating it on a one to four scale. Four-point numeric rating scales have 




4.4.3. Fibromyalgia impact questionnaire 
The Fibromyalgia impact questionnaire (FIQ) is a questionnaire in which a patient 
with FMS is evaluated through self-assessment. It contains two subscales, physi-
cal impairment and symptoms/psychological impairment, which are represented 
by a total of 20 items. The results pertain to the impairments suffered over the 
course of the past week with high scores indicating a high degree of limitation. The 
first eleven items which relate to physical impairment are responded to on a 4-
point Likert-type scale from 0 – 3. Not all items apply to some of the patients, as 
they include certain tasks (washing dishes, shopping, preparing meals, and oth-
ers). The participants are asked to leave out any activities they do not engage in. 
These items then are deleted from scoring. On the next two items the patients are 
asked to circle the number of days of the past week they did not feel well and the 
number of days they were not able to work due to FMS. The remainder of the 
questions pertain to work difficulty, pain, fatigue, morning tiredness, stiffness, anx-




The patients rate those on 100 mm visual analogue scales. The sub scores are 
obtained when the ratings of the first eleven items are summed up and then divided 
by the number of answers given. The score, which ranges from 0-3 is then multi-
plied by 3,33. Item 12 is scored inversely from 0-7 as it indicates the days not 
feeling well. Item 13 is then scored directly, also from 0-7. Both items 12 and 13 
are multiplied each by 1,43, so they yield a score on a 0-10 range. The remaining 
items are scored by measuring the mark on each visual analogue scale with results 
ranging from 0-10. The overall score comprises the sum of all sub scores ranging 




4.4.4. Quality of life scale 
Originally developed by American psychologist John Flanagan over 40 years ago, 
it was designed as a psychometric tool to assess the quality of life in patients with 
acute and chronic illnesses.  
It now comprises 16 items (the more item “independence” was added by Burkhard 
to the 15-item original) of different categories which convey the subjective ap-
praisal of an individual´s contentment with material and physical well-being, rela-
tionships with other people, social, community and civic activities, personal devel-
opment and fulfilment, recreation and independence. For example, patients are 
asked how content they were with their “health, fitness and vitality” or with “having 
kids and raising them”. Each item is rated on a seven-point Likert-type scale rang-
ing (in its German version) from “very satisfied” (=7) to “very dissatisfied” (=1) with 
an overall range between 16 and 112. Healthy populations score at about 90, pa-
tients with rheumatic arthritis, psoriasis, and urinary incontinence at about 83, pa-
tients with fibromyalgia at about 70 (82). 
Several analyses on the scale show that patients with stable diseases (such as 
ostomies) score higher on the QOLS than patients with unstable diseases (such 
as diabetes). Good internal consistency, high test-retest reliability and strong con-





4.4.5. Short form health survey 12 
The short form health survey 12 was originally developed to measure a patient´s 
health-related life quality within the clinical study spectrum. Unlike the quality of life 
scale which focuses on non-health-related aspects of well-being or the lack 
thereof, the short form health survey includes domains related to physical, mental, 
emotional and social functioning. It originally comprised 36 questions covering the 
functional status, the well-being and the general health perception of the 
participant. In order to make the survey more applicable and time efficient, the 
authors decided to create a shortened version of 12 questions at roughly the same 
validity and reliability (84). The SF-12 provides information on the subject’s health 
status through eight sub-domains which are represented by either one or two 
items: General health perception (1 item), physical functioning (2 items), physical 
role functioning (2 items), emotional role functioning (2), bodily pain (2), vitality (1 
item), mental health (2 items), social functioning (1 item). 
For example, the question pertaining to the general health perception is “How 
would you describe your health status in general?”. The question can be answered 
by checking a corresponding statement (e.g. “excellent”, “very good”, “good”, “fairly 
bad”, “bad”). The number of these possible statements varies from 2 to 6. The 
results are displayed by the physical and mental health component summary 
scores (PCS, MCS) which range from 0 to 100, with 0 inferring minimum possible 
and 100 inferring maximum possible health status. A national (U.S.) standard mean 
was established at 50 with a standard deviation of 10. 
Both the PCS and the MCS yield fairly age specific results and comparisons are 
only purposeful when made between a similar aged sample (PCS decreases, MCS 
increases with age) (81). 
 
 
4.4.6. Hospital anxiety and depression scale 
The hospital anxiety and depression scale (HADS) developed by Zigmond and 
Snaith in 1983 to measure the psychological implications of physically ill (non-




which can be completed in less than five minutes not only proved useful to 
determine a patient´s psychological status, but also showed responsiveness to 
changes when treatment was administered. Correlational studies and clinical 
group comparisons are among the most frequent applications of the scale (85). 
The HADS is made up by two 7 item subscales, the HADS-A and HADS-D which 
reflect anxiety and depression, respectively. An item which measures anxiety is 
“sometimes I have an anxious feeling in my stomach area”. One which depicts 
depression is “I can still be as happy today as back in the day”.  
Each item is rated on a 0-3 response category so results both for the HADS-A and 
HADS-D range from 0 to 21. A score of less than 8 displays the normal range, one 
between 8 and 10 indicates a possible mood disorder. A mood disorder is probable 
when patients score more than 10 on HADS-A and HADS-B (80). 
The HADS has been translated into several languages and has shown good 
internal consistency and external validity (86). 
 
 
4.4.7. Mauger forgiveness of self and others 
As an increasing number of scholars and clinicians became aware of the beneficial 
impact of forgiveness, accurate psychometric instruments became necessary. In 
this study, we decided to use the Mauger forgiveness of self (FOS) and others 
(FOO) scales developed in 1992 by Mauger and his colleagues (40). It was 
intended to measure an individual´s inclination to forgive him or herself as well as 
others. Scales on the subject were already available but typically focused solely 
on either forgiveness of self or on forgiveness of others. The Mauger forgiveness 
scale enables researchers to measure and then compare both dimensions. 
Mauger et al. hypothesized that the lack of self-forgiveness resembles an 
intropunitive style, meaning that a person directs blame for incongruent 
expectation/outcome situations toward him or herself (87). On the other hand, they 
proposed that forgiveness of others reflects an extra punitive style, meaning that 
a person is inclined to blame others for apparent wrongdoings, holds grudges and 




In the Mauger scale, both components are measured by 15 items each that are 
corresponded to on a Likert-style scale. Statements like “I feel guilty because I 
don´t do what I should for my loved ones” (which measures self-forgiveness) and 
“It´s hard to forgive those who have hurt me” (which in turn measures forgiveness 
of others) are rated by the examinee choosing one a one (“I strongly disagree”) 
through five (“I strongly agree”) scale. To obtain an overall score, all scores are 
added up. For both subscales, scores between 15 and 75 are attainable.  
Altogether, both scales have shown acceptable reliability and good construct 
validity. Because there was no German version available, we converted the 
English version into German by using back-forward translation.  
 
 
4.4.8. State trait anger expression inventory 
The state trait anger expression inventory (STAXI) has proven useful in clinical 
diagnostics, particularly in psychosomatics. The instrument which was created by 
C.D. Spielberger in 1994 for two primary reasons: to measure anger components 
for in-depth personality assessment to provide a means for tracing how these 
components of anger can mediate the development of medical conditions (88). 
The STAXI comprises of two previously developed inventories conjoined. Those 
are the state trait anger scale and the anger expression scale. The STAXI uses 44 
items to measure five independent anger components. Situational anger (state 
anger) and four dispositional anger components - trait anger, anger-in (or state 
anger inhibition), anger-out (or anger expression) and anger control.  
The items are matched on a four-point response scale from 1 (almost never) to 4 
(almost always). To evaluate the Inventory individual point scores are added up. 
No item inversion is necessary. State and trait anger scores range from 10-40. 
Ranges of anger in, anger out and anger control scores are 8-32. Overall, high 
scores correspond with high levels of the anger (88). The STAXI has shown 
excellent psychometric properties and it has also proven in its German version to 





4.4.9. Anger rumination scale 
The anger rumination scale (ARS) was developed to depict the cognitive process 
which is initiated after the emotion of anger has been incited. The ARS contains 
19 items which load on four dimensions:  
 
1. Angry afterthoughts (6 items) – e.g. “After an argument is over, I keep 
fighting with this person in my imagination” 
2. Angry memories (5 items) – e.g. “I ponder about the injustices that have      
been done to me” 
3. Thoughts of revenge (4 items) – e.g. “I have long living fantasies of 
revenge after the conflict is over” 
4. Understanding of causes (4 items) – e.g. “I think about the reasons people 
treat me badly” 
 
The first two dimensions correspond to the assumption that anger rumination 
involves the process of brooding over an episode of the recent or the distant past, 
which evokes the sentiment of anger in the individual. The other two encompass 
counterfactual thinking as a result of an event involving anger. Counterfactual 
thinking means that an individual retrospectively imagines the outcome of a 
situation other than how it occurred in actuality. For example, a person experiences 
a situation in which he or she is unjustly reprimanded. The person remains calm 
and submissive. An example of counterfactual angry rumination would be if this 
person later thinks: “I should have told him my opinion to his face”. Understanding 
the causes represents the cognitive process of coming to terms with the cause of 
the anger by working through it, eventually reaching a point where it is no longer 
troublesome. Thoughts of revenge can be viewed as an attempt to conclude the 
conflict, but it also implies the desire to become actively engaged in restoring the 
equilibrium (51). All items are intended to be matched on a Likert-type scale from 
one (almost never) to four (almost always). The scores on angry afterthoughts 
range from 6 to 24, thoughts of revenge and understanding causes from 4 to 16 




inclined to think about what is represented by the respective subscale. The scale 
has demonstrated adequate reliability and validity with good internal consistency. 
The reliability coefficients were 0.86 for angry afterthoughts, 0.72 for thoughts of 
revenge, 0.85 for angry memories and 0.77 for understanding causes (51). The  




After we collected the completed questionnaires, the results were recorded and 
analyzed using the computer-based program SPSS (Statistical Package of Social 
Science, SPSS Inc., Chicago, IL, USA; Version 22). 
 
The first step of data analysis was a descriptive analysis which served to define 
both the FMS sample as well as the healthy control group regarding their 
sociodemographic background, their perceived pain, their ability to forgive, etc. 
The data was depicted in tables using mean, standard deviation, standard error, 
minimum and maximum. To detect significant differences between the two groups, 
T-test was used. As both groups had a sufficient number of participants (n>25), 
normal distribution was assumed (89). 
 
Thus, according to scientific standards we used the following levels of significance:  
 Probability of Error  (p)   <   0,05    significant 
    (p)   >   0,05    not significant 
 
In order to elucidate correlations of the results of the Mauger forgiveness scale, 
the state trait anger expression inventory and the anger rumination scale with 
health scales, we used Pearson correlation coefficient r for each subcategory. 
Pearson’s correlation coefficient is an instrument to measure monotonous correla-




positive r values, negative correlations with the opposite. If r equals zero, no mo-
notonous correlation was detected. A strong correlation can be assumed if r is 
close to -1 or 1; r close to 0 indicates little or no correlation between the variables.  
We used G*Power: Statistical Power Analyses for Windows and Mac (Version 
3.1.9.7.), an open source tool by the Heinrich Heine Universität Düsseldorf to per-




5.1. Missing data 
Altogether, the rate of missing data was less than 13 % on all scales.  
On the pain today scale no missing data was detected. The highest rates of 
missing data were on the Fibromyalgia impact questionnaire (12,13 %) and the 
SF-12 PCS and the MCS (both 11,56 %). 
 
 
5.2. Post hoc power calculation 
Post-hoc power calculations revealed a power of >0.99 (forgiveness of others: 
36.59 vs. 33.61) and therefore was considered sufficient. 
 
 
5.3. Sociodemographic analyses 
The sociodemographic component of the survey provides general information on 
the patients and the controls who participated in this study. In addition, it was used 
to determine significant differences in both study populations on their social and 
demographic background.  
The mean age of the FMS patients was 58,05 with a standard deviation of 14,21. 
The youngest patient who participated was 28, the oldest 81 years of age. The 
controls were younger. Their mean age was determined 46,95 with a standard 




To detect differences between the two groups, the Pearson´s Chi Squared test was 
applied.  
Table 3: Sociodemographic analyses 
 
  FMS Patients  Controls   
  absolute relative (%) absolute 
relative 
(%) (p) 
Age   46,95   58,05   <0,01 
Sex 
female 161 94,7 76 94 
0,78 
male 9 5,3 5 6 
Religion 
christian 138 81,18 65 80,25 
0,11 
muslim 1 0,6 4 4,94 
other 1 0,6 0 0 
no religion 30 17,65 12 14,81 
Marital   
Status 
married 125 73,53 49 62,82 
<0,01 
living with 
partner 5 2,94 10 12,82 
divorced 16 9,41 8 10,26 
living 
alone 8 4,71 8 10,26 
widowed 16 9,41 3 3,85 
Education 
9 years 73 43,72 7 8,86 
<0,01 
10 years 65 38,92 23 29,11 
13 years 
and more 16 9,58 44 55,7 
other 13 7,78 5 6,33 
 
 
The data shows that both groups comprise mainly women. As to their religion, both 
groups consider themselves mostly Christian (FMS: 81,18% vs. controls: 80,25%). 
17,65% of patients with FMS and 14,81% of healthy controls stated they had no 
religion. The Pearson´s Chi Squared test shows that differences in religion are not 




The majority of both groups is married (FMS: 73,53% vs. controls: 62,82%), but 
the marital status differs significantly. Patients are less likely to live alone and more 
likely to be widowed than their healthy counterparts.  
The biggest difference between the two groups is their educational backgrounds. 
The controls are mostly educated 13 and more years while the majority of patients 
went to school for nine years and only a minority (9,58%) had 13 and more years 
of education.  
 
 
5.4. FMS symptom expression 
The following data is intended to demonstrate that the FMS patient sample, in fact, 
suffers from FMS related symptoms and that the healthy controls were free of FMS. 
Moreover, it shows that the healthy controls are not suffering from another pain 
related disorder.  
 
 




n Mean Standard Deviation 
Standard 
Error Min. Max. (p)  
Pain duration 
in years 
FMS 165 18,07 10,85 0,84 2 52 
<0,01 
controls 65 1,05 4,5 0,58 0 32 
Pain today  
FMS 173 6,18 1,74 0,13 1 10 
<0,01 




FMS 172 6,76 1,63 0,12 1 10 
<0,01 
controls 76 0,95 1,53 0,18 0 6 
 
 
The results displayed in the table show that both groups differ significantly. Even 




in patients with FMS as well as FMS related symptoms is far greater in the patient 
sample.  
Their mean duration of pain was 18,1 years compared to the control´s 1,5 years. 
Seven of the controls state a pain duration from half a year to 32 years. Fifty-two 
of the controls reported no pain duration; the median was 0. The control´s median 
is also 0 on the pain today and pain severity last three months subscales. Thus, 
we can show that both groups represent each a sample of patients with FMS and 
one of FMS-free individuals. 
 
 
5.5. QOLS, FIQ, HADS and SF-12 
The following descriptive statistics show how FMS patients and the sample of 
healthy controls score on the quality of life scale, the Fibromyalgia impact 
questionnaire, the hospital anxiety and depression scales and the SF-12 MCS and 
PCS.  
Table 5: FMS symptom burden in patients and controls 
 
  n Mean  Standard Deviation  
Standard 
Error Min.  Max.  (p) 
QOLS 
FMS 172 66,27 16,62 1,27 19 104 
<0,01 
controls 79 88,47 14,48 1,63 32 108 
FIQ 
FMS 152 50,22 12,16 0,99 18,7 76,67 
<0,01 
controls 26 11,98 11,85 2,32 0 50,68 
HADS-A 
FMS 170 10,59 4,59 0,35 0 21 
<0,01 
controls 81 4,77 3,09 0,34 0 13 
HADS-D 
FMS 170 9,42 3,95 0,3 1 20 
<0,01 
controls 81 2,7 2,69 0,3 0 14 




PCS controls 66 54,48 5,04 0,62 36,79 61,94 
SF-12 MCS 
FMS 153 35,62 9,06 0,73 15,26 59,44 
<0,01 
controls 66 50,34 8,92 1,1 24,51 64,08 
 
 
QOLS = quality of life scale, FIQ = Fibromyalgia impact questionnaire, HADS-A = hospital 
anxiety and depression scale subscale anxiety, HADS-D = hospital anxiety and depression 
scale subscale depression, SF-12 PCS = short form health survey physical component 
summary, SF-12 MCS = short form health survey mental component summary 
 
The scores produced by FMS patients and healthy controls differ significantly on 
all scales. On the quality of life scale, the healthy sample score a mean of 88,47 
which is congruent with scores of around 90 for healthy individuals proposed by 
the author of the scale (82). The FMS sample present with a slightly lower mean 
value of 66,27 compared to the mean of 70 established by the validation study for 
FMS populations (82). FMS scored a mean of 50,22 on the Fibromyalgia impact 
questionnaire which ranges from 0 to 100. As to be expected, to healthy controls 
score drastically lower, with a mean of 11,98. On the hospital anxiety and 
depression scale, the FMS patient´s mean for the anxiety subscale was 10,59 
(compared to 4,77 of controls) and 9,42 for the depression subscale (compared to 
2,7 of controls). According to the scale´s author´s interpretation, the average 
patient with FMS has a probable anxiety and depressive disorder, while the healthy 
sample´s results were within the normal range. In the SF-12 PCS and MCS mean 





We employed the Mauger forgiveness scales to measure both samples´ tendency 
to forgive themselves as well as others. The results of the both forgiveness 







Table 6: The ability to forgive oneself and others 
FMS patients (n = 171) vs. Controls (n = 81) 
 
    Mean Standard Deviation 
Standard 
Error Min Max (p) 
Self-for-
giveness 
FMS  38,43 11,04 0,84 15 63 
<0,01 
Controls 30,51 10,21 1,13 17 73 
Forgiveness 
of others 
FMS  36,59 9,39 0,72 17 63 
0,19 
Controls 33,61 9,27 1,03 18 59 
 
Range: Forgiveness minimum=25; maximum=75.   
 
The patient sample presents a mean of 38,43 on self-forgiveness compared to 
30,51 of the control. High scores correspond with low levels of self-forgiveness 
which shows that patients with FMS are less inclined to self-forgive than their 
healthy counterpart. The difference detected here is highly significant. Of a 
maximum of 75 points attainable, the mean of FMS patients other-forgiveness 
score is at 36,59 compared to 33,61 of the control group. Thus, patients with FMS 
score higher on forgiveness of others (which implies a lower level thereof) 





To measure the sample´s levels of anger we employed the state trait anger 
expression inventory. The results on all five subscales which are part of the STAXI 





Table 7: Anger Expression 
Controls (n = 81) vs. FMS patients (n = 172) 
 
  Mean Standard Deviation 
Standard 
Error Min. Max. (p) 
State anger 
(S-A) 
FMS 15,36 6,76 0,52 10 40 
<0,01 
controls 11,69 3,57 0,40 10 31 
Trait anger 
(T-A) 
FMS 21,75 5,68 0,43 10 40 
<0,01 
controls 19,16 4,54 0,5 12 35 
Anger-in 
(A-I) 
FMS 20,35 5,07 0,39 9 32 
<0,01 
controls 15,51 4,4 0,49 8 26 
Anger-out 
(A-O) 
FMS 13,49 3,96 0,30 8 27 
0,84 
controls 13,39 3,94 0,344 8 28 
Anger    
control 
(A-C) 
FMS 22,21 4,16 0,32 12 32 
0,07 
controls 23,25 4,47 0,5 12 32 
 
Ranges: S-A, T-A: 10 – 40; A-I, A-O, A-C: 8-32 
 
Significant differences between the two groups are observed in state anger, trait 
anger and anger in.  
The greatest difference between the two groups are observed in state anger 
results. The patient mean of state anger was 32,4% above that of controls. Another 
difference can be traced in the subscale anger-in. Here, the mean of the patients´ 
sample is 31,2% higher than that of the control group. Also, trait anger is 13,5% 
higher in the patient sample. The results on the remaining subscales anger-out 
and anger control are deemed not significant.  
Altogether, the results of the state trait anger expression scale depict the patients 
with FMS as people who are struggling with unhealthy levels of momentary anger. 




not outwards against people or objects but instead inwards toward themselves. !
 
 
5.8. Anger rumination  
We used the anger rumination scale to outline a propensity to ponder on life events 
of the past.  
 
Table 8: Anger Rumination 
Controls (n = 81) vs. FMS patients (n = 172) 
 
 
Mean Standard Deviation 
Standard  
Min. Max. (p) 
  Error 
Angry after-
thoughts 
FMS 2,44 0,83 0,38 6 29 
<0,01 
controls 1,83 0,64 0,43 6 21 
Thoughts of re-
venge 
FMS 1,6 0,51 0,16 4 14 
<0,01 
Controls 1,45 0,47 0,21 4 13 
Angry      
memories 
FMS 2,5 0,81 0,3 5 20 
<0,01 
Controls 1,80 0,62 0,34 5 19 
Understanding 
causes 
FMS 2,50 0,81 0,25 4 19 
<0,01 
controls 2,1 0,68 0,3 4 15 
Anger rumina-
tion scale total 
FMS 2,26 0,65 0,95 19 73 
<0,01 
controls 1,8 0,5 1,06 19 63 
 
Range of all scales: 1-4  
 
The scores of all anger rumination subscales are significantly different. The patient 




group. Of all anger rumination subscales, we find the greatest difference between 
the two groups here. The results of the subscale angry memories show a great 
difference between the two groups, with patients´ mean at 31,0% above controls. 
The mean of understanding causes was 19,0% higher than the control group. On 
thoughts of revenge the two groups are closer together, with a patient mean of 
10,3% above that of healthy controls. When all items of the anger rumination scale 
are added up, the mean of the FMS sample was 25,2% higher than that of the 
control group. These results show that patients with FMS are overall more inclined 
to ponder over anger episodes. Especially ruminative thoughts on anger related 
events of the near and distant past are more likely to be experienced by FMS 
patients compared to healthy persons. They also engage in more counterfactual 
thinking when processing anger episodes.  
 
 
5.9. Correlations of Mauger scales, STAXI and ARS with FIQ, HADS, SF-
12 and QOLS  
Pearson correlation coefficient r was calculated to illustrate FMS patients´ 
correlations between the subscales of Mauger forgiveness scale, state and trait 
anger expression scale and the anger rumination scale with the FIQ, the HADS 
scale, the SF-12 components and the QOLS. 
 
Table 9: Correlations of Mauger scales and STAXI with 
FIQ, HADS, SF-12 and QOLS 




Others (r) 0,07 0,23** 0,22** -0,02 -0,09 -0,29** 
Forgiveness of 
Self (r) 0,30** 0,58** 0,45** -0,07 -0,41** -0,43** 
State Anger (r) 0,31** 0,33** 0,37** -0,10 -0,30** -0,40** 




Anger in  (r) 0,20* 0,40** 0,38** -0,04 -0,26** -0,24** 
Anger out (r) 0,15 0,21** 0,23** -0,05 -0,16** 0,28** 
Anger Control (r) -0,10 -0,03 -0,10 -0,01 0,05 0,21** 
    * (p) = <0,05 ** = (p) <0,01 
 
 
QOLS = quality of life scale, FIQ = Fibromyalgia impact questionnaire, HADS-A = hospital 
anxiety and depression scale subscale anxiety, HADS-D = hospital anxiety and depression 
scale subscale depression, SF-12 PCS = short form health survey physical component 
summary, SF-12 MCS = short form health survey mental component summary, (r)= 
Pearson correlation coefficient 
 
 
Self-forgiveness shows the highest correlations both positive and negative, in 
particular with HADS-Anxiety, HADS-Depression, SF-12 MCS and the quality of 
life scale. This indicates that FMS patients who forgive themselves less reported 
higher FMS symptom severity, more anxiety and depression, less mental health 
and a lower quality of life. There was also a significant correlation with less FMS 
impairment as measured by the FIQ. 
In order to discover which aspects of FMS impairment profited the most from self-
forgiveness, we also correlated with the FIQ subscales. Self-forgiveness only 
showed a significant correlation with sleep quality (r=0,17*), but none with physical 
impairment (r=0,13), well-being (r=0,87) and fatigue (0,15). 
Forgiveness of others show significant correlations, too. Those correlations, 
however, are lower. Moreover, the anger subscales state anger, trait anger, anger 
in and anger out also show significant correlations with the symptom expression 
and life quality scales; state anger correlating the most with high symptom 
expression and low quality of life, followed by trait anger, anger in and anger out. 
Anger control show a positive correlation with quality of life only. Though none of 




anger control only shows a significant correlation with the QOLS, all other 
correlations were insignificant.  
 
 
Table 10: Correlations ARS with FIQ, HADS, SF-12 and QOLS 
 




revenge (r) 0,08 0,21** 0,31** -0,01 -0,15 -0,31** 
Angry after-
thoughts (r) 0,24** 0,46** 0,43** -0,05 -0,23** -0,31** 
Angry memo-
ries (r) 0,30** 0,43** 0,42** -0,09 -0,30** -0,35** 
Understand-




(r) 0,27** 0,45** 0,44** -0,07 -0,27** -0,34** 
     * (p) = <0,05             ** = (p) <0,01 
 
QOLS = quality of life scale, FIQ = Fibromyalgia impact questionnaire, HADS-A = hospital 
anxiety and depression scale subscale anxiety, HADS-D = hospital anxiety and depression 
scale subscale depression, SF-12 PCS = short form health survey physical component 
summary, SF-12 MCS = short form health survey mental component summary, (r)= 
Pearson correlation coefficient r 
 
The data suggest that FMS patients who score high on angry afterthoughts, which 
represents rumination of recent events, show high FMS symptom expression, 
anxiety and depression, as well as low mental health and low quality of life. The 




symptoms, physical and mental health. Significant correlations, though, are 
detected with anxiety and depression, as well as with low quality of life. As with 
forgiveness and the STAXI mentioned in the previous chapter, none of the ARS 
subscales correlate significantly with physical health.  
A correlation analysis of the ARS subscales with the FIQ subscales fatigue and 
sleep quality was performed. We found significant correlations between angry 
afterthoughts and fatigue (r=0,44**), angry memories with both fatigue (r=0,54**) 
and poor sleep quality (r=0,39**). The subscale understanding causes also 




6.1. General information  
As we recruited our FMS patients through self-help groups which had mostly 
female members, the overwhelming majority of the FMS patients participating in 
this study were female. The religious affiliation is similar in both groups with a 
majority of Christians in both groups. We find that our sample of patients with FMS 
was less educated than the group of healthy controls chosen at random. In our 
sample, the majority of patients with FMS has 9 years of schooling. Only 9,6% 
have 13+ years of education. Both a lower educational status in FMS patients 
compared to the general population, as well as mainly basic education have been 
described by several other studies (1). The overall FMS burden of FMS patients is 
similar to other studies also using the FIQ on Fibromyalgia patients to measure 
symptom expression (90). The amount of pain experienced by the probands at the 
time of the survey is congruent with preexisting FMS research (91). Altogether, the 
rate of missing data is relatively low at 13 % on all scales. Other studies including 
FMS patients reported similar rates (e.g. (92)). One possible explanation for the 
missing data could be our failure to stress the importance of completion to the 
examinees even if certain questions seem to have no immediate personal 





6.2. Forgiveness in patients with FMS 
6.2.1. Self-forgiveness 
As we suspected, FMS patients show a lowered capacity to forgive altogether. Our 
results show that it is particularly hard for patients with FMS to forgive themselves, 
even more so than forgiving others. Patients with FMS experience internal conflict 
as they fail to come to terms with their own transgressions. Other research 
conducted on the psychology of FMS patients have produced similar results.  
Even though a specific Fibromyalgia personality could not be identified, several 
studies have attributed behavioral patterns to FMS patients which are centered 
around over-commitment and perfectionism. When these high standards are not 
met, this is often viewed as failure and can entail stern self-criticism and brutal self-
judgement (93,94). It has been theorized that self-deprecation could be rooted in 
events which require self-forgiveness. Intuitively, this connection seems logical 
because self-forgiveness is characterized by dealing with one´s own shortcomings 
in a friendly, gracious manner. In a study by Kempke et al., a connection was 
established between high levels of self-criticism and grave symptom severity in 
chronic pain patients (95). The ability to forgive oneself could serve as a tool to 
approach perceived failure more clemently. This could be useful because it would 
decrease harsh self-treatment and thus decrease FMS symptom severity caused 
by the subsequent elevated stress levels. The inability to live up to one´s own 
standards can also result in feelings of shame. Both are strong negative emotions  
linked to the experience of pain (96). In a study conducted by Gustavsson et al., 
chronic pain patients also mentioned an overall sense of shame because their 
sickness is often doubted by family, friends and even healthcare professionals. 
This even led some patients to doubt their own pain and think of themselves as 
hypochondriacs (96).  
Moreover, shame often plays a big role in the aftermath of sexual abuse which is 
prevalent in many FMS patients´ biographies (72). Shame has been described as 
a strongly negative emotion centered around self-condemnation and the desire to 
hide oneself (97). Across many cultures, feelings of shame are found in the context 




As perpetrators often condemn their victims (99) and some societies even place 
the responsibility for the wrongdoing on the victim (100), the survivors are left with 
feelings of shame (100). Shame has been reported to be a key personality trait 
preventing self-forgiveness (101).  
Our patients score high on anxiety and depression. Meanwhile, one of the highest 
correlations observed in all items was self-forgiveness with anxiety, and secondly, 
self-forgiveness with depression. The association of self-forgiveness with anxiety 
was already established. In a sample of 324 healthy undergraduate college 
students, John Maltby and his research group established a link between the 
failure to forgive oneself and higher scores in anxiety and depression 
questionnaires. They argued that this was because, being unable to forgive oneself 
was “intropunitive”. Interestingly, this corresponds with the self-critical character of 
FMS patients as indicated above (87).  
 
 
6.2.2. Forgiveness of others 
FMS patients experience much emotional and physical maltreatment at various 
stages of their lives which can result in heightened stress levels and increased 
symptom burden even years after an incident (102). Acquiring a better ability to 
forgive others can help replace negative feelings towards a perpetrator with 
positive emotions. Thus, an old stressor can be removed, and relationships 
restored.   
Many FMS patients have suffered traumatic childhood experiences. Boisset-Pioro 
demonstrated an association between FMS and the frequency and severity of 
sexual and physical abuse during childhood (73,103). Childhood abuse by parents 
of caregivers has been linked to abnormal brain development and stress reactivity 
(104). 
Moreover, in a qualitative study, Sigurdardottir and Halldorsdottir interviewed 
seven pain patients, including five FMS patients, who had been subjected to sexual 
violence in their childhood. All interviewees reported ongoing suffering in various 




Aside from sexual and physical abuse, childhood adversities such as little 
emotional and physical affection by both parents, witnessing parental fighting, 
alcohol and substance abuse are common (106). Because of the aforementioned 
tendency to process interpersonal conflicts rather by internalizing than by 
proactively solving them, FMS patients often experience continuous anger, 
resentment and distress. These sentiments which have been linked to higher FMS 
symptom expression (107).  
Forgiveness as a component of FMS treatment has already been proposed to 
successfully ameliorate FMS health in abuse survivors (108). Lee et al. 
investigated the positive effect of forgiveness in a forgiveness intervention study 
on FMS patients who had suffered emotional or physical maltreatment by their 
parents. A forgiveness intervention based on Robert Enright´s book “forgiveness 
is a choice” (109) was focused on teaching the participants how to transform their 
anger against their parents into positive thoughts, feelings and behaviours through 
forgiveness. The results were compared to another FMS sample who received a 
health intervention. After a meeting weekly for 24 weeks, the patients who had 
received the forgiveness intervention demonstrated lower anger-levels and better 
FMS health compared to the sample who had undergone the health intervention.  
FMS also poses a challenge in the workplace. In a study conducted by Henriksson 
et al., 75% of the interviewees with FMS stated that the disease had influenced 
their ability to perform at work. 52% said that FMS related symptoms forced them 
to work shorter hours and 38% needed more breaks to recover. The negative 
impact of this reduced productivity is two-fold: Because their work role tends to be 
very important for FMS patients sense of identity and self-esteem (110). The failure 
to perform at the same level as their coworkers can result in feelings of 
worthlessness, shame and guilt. In addition, FMS often face disapproval of their 
coworkers because of their decreased productivity and even bullying is common 
(111). This can lead to a toxic work relationship resulting in hostile feelings towards 
colleagues.  
Forgiveness could serve to mediate workplace-related stress. On the one hand, 




consolidating a patient´s self-worth. On the other hand, forgiving the colleagues 
for mistreating them could reduce feelings of anger and hostility towards them. 
Moreover, increasing forgiveness of others could lead to a healthier interaction 
with family and friends. This could be particularly interesting for FMS patients be-
cause relationship quality is known to suffer from FMS. Studies have well docu-
mented that the struggle with FMS can take a heavy toll on a patient´s relationship 
with their spouse, children and close friends. The anger and distress experienced 
by patients with FMS along with comorbid mood disturbances (112) is often chal-
lenging for attachment figures. A gradual downsizing of the social group ensues.  
It is commonly understood that this relational backup is beneficial for all human 
beings who struggle. In times of hardship, a sympathetic ear or a helping hand can 
give the strength to move forward and overcome barriers. A decline in the relation-
ship quality with allies, or their withdrawal altogether, interferes with this salutary 
pathway (113,114). 
Of course, this also applies to patients with chronic conditions. Naturally occurring 
social support has shown to facilitate the recovery, rehabilitation and the adaption 
to chronic disease (115). Therefore, it is not surprising that strong relational backup 
has shown a positive effect on the well-being of FMS patients (116).  
Forgiveness has been described a potent strategy to solidify relationships (117).  
According to Offenbaecher et al., facilitating the ability to forgive others could also 
lead to the acquisition of other beneficial characteristics like empathy, compassion, 
altruism and commitment (96). Given the specific psychosocial challenges posed 
by FMS patients on their environment, forgiveness could be a key strategy to build 
bridges. It would be a way to address the adversities of life through reappraisal of 
negative sentiments towards others and replacing them with benevolent, charita-
ble ones. As a consequence, simmering conflicts could be solved more healthily 








6.2.3. Forgiveness and health 
When Mauger et al. (40) used their scale to examine the differences of health-
related benefits of being able to self-forgive and to forgive others among a sample 
of 237 outpatient counseling clients they found a stronger positive correlation of 
self-forgiving to mental health aspects such as depression, anxiety and anger, 
compared to forgiving others. The relationship of forgiveness and 
depression/anxiety has also been established in a case-control study involving 
incest victims. The victims met once weekly with a counselor for an average of 
14.3 months. When the program was over, they reported lower levels of depression 
and anxiety, as well as self-esteem improvement (118). This is particularly 
interesting in the fibromyalgia context because the incest prevalence in FMS 
patients was found to be higher than in the general population (119). 
We also find self-forgiveness to be positively associated with less FMS related 
symptoms, better mental health and less anxiety and depression. Regarding FMS 
related symptoms, self-forgiveness in particular showed a positive correlation with 
sleep quality. Toussaint et al. also found forgiveness and sleep quality to be linked 
to each other when they assessed a representative sample of 1,423 American 
adults interviewed by telephone (120). Self-forgiveness in particular has been 
theorized to have health benefits mediated by sleep quality (45). Sleep physiology 
disturbances such as early morning awakenings, insomnia and feeling tired when 
waking up are common in FMS patients (3). Toussaint et al. hypothesized that 
forgiving may level stressful emotions such as anger, regret and rumination that 
arise during the day and provide a calm mental state which supports replenishing 
sleep at night. Sound sleep, in turn, being the mediator to better health (120). It 
would be interesting shed some light on the connection of self-forgiveness and 
FMS health through sleep quality, for example by comparing the sleep quality of 
an FMS sample which receives an intervention based on self-forgiving with that of 
one that receives a health intervention.  
Another explanation why self-forgiveness is particularly beneficial for FMS patients 
was provided by Hall and Fincham. Within the reconciliation context they 




possible to avoid the transgressor (121). Negative feelings, thoughts and 
behaviors typically emerge when the victim meets the perpetrator. That is why the 
negative impact of not forgiving someone else can be reduced by avoiding the 
transgressor. In a self-forgiveness context, this is not possible. One has to 
continuously face the offender and at the same time endure the backlash of the 
unresolved conflict. It seems reasonable that mental health deterioration is a side 
effect of this process.  
Recent research on the beneficial properties of forgiveness has demonstrated 
better psychological and physical health also in forgiving individuals without FMS 
(122). Contrarily, a chronic state of unforgiveness has been hypothesized to 
negatively influence the immune system via increased stress levels, increased 
cortisol and adrenalin secretion together with the dysregulation of the immune 
system on the cellular level (123).  
The pathogenesis of FMS is multifactorial. Aberrations of the hypothalamic-
pituitary-adrenal axis as part of the vegetative response to stress have been 
subject to discussion and even a link between plasma cortisol and pain was 
established (19). Worthington and Scherer stated that forgiving a wrongdoer has 
the opposite effect, resulting in lower levels of stress and a better functioning 
immune system. Also, they found high levels of forgiveness to positively influence 
the behavioral activation system which manages positive and negative emotions 
and the behavioral inhibition system limiting anxiety (122). This corroborated 
earlier findings that people with a strong propensity to forgive were less likely to 
struggle with anxiety and depression related diseases (124). Our results are in line 
with the aforementioned prior research.  
Heinze and Synder found negative correlations of forgiveness with the symptoms 
of posttraumatic stress disorder when they used the Heartland Forgiveness Scale 
on a sample of persons who had undergone childhood trauma such as physical or 
sexual abuse (125). As previously indicated, such traumatizing events are also 
often part of a FMS patient´s biography. Moreover, a significant overlap of the two 
diseases regarding the current diagnostic criteria for FMS and PTSD has been 




patients with FMS, which in turn highlights the qualities of forgiveness on the 
psyche of FMS patients. 
Our study is among the first, to our knowledge, which distinguishes forgiveness 
of self from forgiveness of others and their respective association with FMS 
health. Self-forgiving seems to have a bigger impact than forgiving others. This 
was proven to be the case not only with FMS patients but also when forgiveness 
related health benefits were assessed in healthy individuals. Macaskill asked 295 
college students to complete questionnaires on forgiveness and health (among 
others). She found no correlation between forgiveness of others with better men-
tal health, whereas self-forgiveness was a predictor thereof (126).  
 
 
6.3. Anger in patients with FMS 
6.3.1. Anger Expression 
The emotion-focused assessment of anger in patients with FMS and healthy 
controls that we performed in this study shows significant differences in some, not 
all, aspects of how both groups grapple with their own anger.  
The high levels of state anger exhibited by our patient sample means that they 
experience anger more often and more intensely than healthy individuals. In other 
words, they are constantly in a state of anger. However, the anger is not aimed at 
other persons or objects, as anger-out levels are normal. Instead, high levels of 
anger-in suggest that it is directed inwards toward the person itself.   
High levels of anger have proven harmful to a person’s physical health as various 
studies of the past have shown. Our study also presents significant correlations of 
anger aspects with health, anxiety, depression and lower life quality.  
High levels of anger have proven harmful to a person’s physical health as various 
studies in the past have shown. Anger prone people are more likely to develop 
hypertension (127,128), coronary heart disease (127,129) and glucose tolerance 
issues (130). This has largely been attributed to the anger induced stress response 




A pain amplifying quality of anger in chronic pain patients has also been described. 
In a study by van Middendorp et al. (107) women with and without FMS recalled a 
neutral event, an event which had made them angry and one that made them sad. 
After each story, they were exposed to mild shocks of electrical current to measure 
pain threshold change. The researchers found that anger and sadness were risk 
factors for increased pain as anger predicted both FMS related clinical and 
electrically stimulated pain perception. This shows that anger should be 
understood as a sentiment which amplifies preexisting pain in patients with FMS. 
Our results show high levels of anger in FMS patients; hence it seems likely that a 
reduction thereof would reduce pain sensation.  
Our results also show that high levels of anger directed inwards are common in 
patients with FMS. This is in accordance with prior research. Seyar et al. came to 
the same conclusion when conducting anger assessments on patients with FMS, 
patients with rheumatoid arthritis and a healthy control group. They found that FMS 
patients were more likely to suppress and internalize anger compared to the other 
two groups (131). 
Studies on the internalization of anger in chronic pain patients have shown that a 
practice of inhibiting the expression of anger may be a predictor of pain intensity 
(132). This begs the question if an intervention which is focused on reducing the 
internalization of anger and educating the patients on how to express their anger 
healthily would be useful for patients with FMS. Besides high levels of anger, the 
patient sample which participated in this study also shows relevant mental health 
impairment including depression and anxiety. Positive correlations between the 
anger subscales with depression indicated a possible relationship. This 
relationship has been reported in prior studies (109).  
Some theorists propose that anger is the source of significant internal conflict to 
people who are suffering from depression, because feelings and actions 
dominated by the anger often result in guilty feelings and self-criticism (133). In 
other words, anger often triggers irritable and aggressive behavior which produce 




Both within and outside the scientific field, there is a wide understanding that 
depression is anger directed inward. While this may be a gross oversimplification 
of the phenomenon, studies show that people who suffer from depression are more 
likely to direct anger inwards than healthy individuals (134).  
The tendency to internalize and suppress anger has particularly been linked to 
depression via elevated stress levels (135).  
Therefore, effective anger management could be a promising tool to also reduce 
comorbid depression in FMS patients. 
 
 
6.3.2. Anger and forgiveness 
Many share the belief that anger is the largest obstacle in achieving forgiveness 
(136). Our results show that forgiveness has an inverse association with almost all 
anger subgroups. High levels of self-forgiveness correlate negatively with anger 
in, anger out, state and trait anger. Only anger control levels were independent 
from self-forgiveness. Forgiveness of others also correlates with lower levels of all 
anger subscales, and even positively with anger control. The inverse correlation of 
forgiveness with anger has been stated by other research. In her dissertation, 
Mauren Anderson found forgiveness to have a diminishing effect on anger 
expression while it was boosting anger control (137). The subscale anger control 
conveys an individual´s ability to control the expression of anger towards a person 
who has caused them to feel angry. On the other hand, forgiveness of others is 
considered the intentional letting go of negative feelings toward other people. 
Therefore, it is not surprising that other forgiveness correlates with anger control. 
This is the first study, to our knowledge, which examines the differences between 
self-forgiveness and forgiveness of others and their association on anger in an 
FMS patient sample.  
Nevertheless, the correlation between forgiveness and anger has already been 
subject to research. Carson et al. found negative correlations between other-
forgiveness and measures of state anger, trait anger, anger in, and anger out. They 




on a patient sample with chronic lower back pain. A difference between self and 
other forgiveness was not made (131). State anger is representing the momentary 
level of anger perception and trait anger conveys the likelihood to react angrily. 
Kim-Prieto et al. associated trait anger with high levels of unforgiveness in a 
sample of healthy individuals (138). Our results, too, show that the association of 
forgiveness is particularly strong with the anger subcategories trait anger and state 
anger. This indicates that being able to forgive has a strong inverse relation with 
the situational anger experience and less with how the anger is dealt with 
(represented by anger-in and anger-out).  
Also, our results indicate that self-forgiveness and other-forgiveness correlate with 
reduced anger equally, with the exception of anger management. Conversely, 
when assessing healthy individuals, research has indicated only other-forgiveness 
to correlate with anger (139). This disparity could be caused by the specific 
behavioral patterns attributed to FMS patients, like over-commitment and 
perfectionism. It seems likely that those are negatively associated with self-
forgiveness, which represents the way one deals with one´s own failures. 
Anger sets off a physiological sympathetic reaction with HPA activation and stress 
hormone secretion, which in turn has shown to worsen FMS symptoms. In order 
to take control of their anger, FMS patients could profit from a wide array of anger 
management tools and techniques. Relaxing by focusing on one´s breathing, 
cognitive restructuring which means replacing highly emotional and dramatic 
thoughts with more rational ones, using humor or adopting better communication 
skills are just some of them (140).  
Also, further research should focus on the mediating role of forgiveness in the 
anger-stress relationship. If forgiveness inversely correlates with anger levels, 
maybe forgiveness-based strategies to manage anger evoking situations could 
lead to better FMS health through reduced anger induced stress levels. As our 
findings suggest, the focus of such strategies should be equally on forgiving 






6.4. Anger rumination in patients with FMS 
6.4.1 Anger rumination 
Anger is an emotion which usually fades away after a short period of time, along 
with the physiological activation that comes with it. Anger rumination has been 
defined as a repetitive thinking style focused on causes and consequences of 
anger.  
Excessive self-focused attention has been linked with several clinical disorders 
(141) and a style of ruminative thought has been associated with dysphoria, 
anxiety and general negative affect (142). This association is apparent in our study 
as well, with anger rumination correlating with anxiety and depression, as well as 
with poor mental health.  
Because FMS has been linked to high levels of anger (135), we wanted to 
investigate how FMS patients deal with past anger episodes and how that differs 
from healthy individuals. The FMS patients who participated in this study score 
higher levels of anger rumination, compared to the healthy control group. The 
results of the anger rumination scale indicate that patients with FMS struggle to 
cognitively put past anger episodes to rest and therefore brood over them for a 
longer time than healthy people. Patients not only obtain a higher total score; they 
also score higher on all four anger rumination sub-dimensions of the scale.  
The results of our sample of healthy individuals are mostly congruent with 
preexisting samples. Compared to the sample Sukhodolsky et al. (143) used to 
validate their own scale, their probands scored very similarly. The only notable 
difference was on the subscale angry memories, with our healthy sample scoring 
less than Sukhodolsky´s.  
The FMS patients who participated in our study present high levels of angry 
afterthoughts and angry memories compared to the sample of healthy individuals.  
They are also much higher than the results obtained by previous research 
assessing healthy persons. Compared to a study involving healthy British women, 
our patients score much higher on angry afterthoughts and angry memories (143).  
The results represent the thinking over past harmful experiences, angry 




recalling those of the more distant past. The patients are also more likely to 
fantasize of taking revenge on the person who did them wrong. When we compare 
the FMS patients´ scores on thoughts of revenge with those on quality of life, a 
negative correlation becomes apparent. 
A negative association between vengeful behavior and general health perception 
has been established by preexisting research (144). Therefore, it seems likely that 
it may take a toll on FMS patients health as well. 
The patients who participated in the present study show an overall higher tendency 
to ruminate angry episodes, as the sum of the means of all items combined is 
significantly higher with FMS patients, compared to the healthy control group. 
Kassinove and Sukhodolsky hypothesized that anger-in could be the pathway for 
future angry rumination (52). Our findings point in the same direction as high levels 
of both anger-in and of anger rumination are found in FMS patients. 
Some research has been conducted linking anger rumination to sleep quality.  
Our results suggest a link between thinking about past anger episodes and 
increased fatigue. Thoughts of anger evoking events of the recent past even 
correlate with poor sleep quality.  Stoia-Caraballo et al. were able to demonstrate 
that anger rumination functions as a mediator between sleep quality and 
forgiveness. This suggests that comorbid sleep disturbances in patients with FMS 
could be reduced via enhanced forgiveness and thus lowered levels of anger 
rumination (145). Anger rumination has shown to be a maladaptive cognitive 
mechanism to cope with a past wrong. In a study, Ray et al. asked two groups of 
probands to think about anger eliciting events in two ways. One was supposed to 
think about it in an angry, ruminative style. The other group was assigned to 
reappraise the event. Compared to reappraisal, angry rumination resulted in a 
stronger anger experience, more perseverative thinking over time and a greater 
sympathetic activation leading to more physiological stress (146). This indicates 
that anger and anger rumination are important and intertwined factors in the 
processing of psychologically stressful situations. This mechanism has also been 




rumination and worry are maladaptive responses to conflict more often exhibited 
by patients with FMS than healthy individuals (36).  
Psychological stress leads to sympathetic activation which, in turn, has shown to 
promote the development and upkeep of FMS. Our results show that participating 
patients with FMS do indeed struggle with high levels of both anger and anger 
rumination. Reviewing the Ray et al. (146) study poses the question if decreasing 
anger rumination in patients with FMS might reduce what they provoke – a stronger 
anger experience and greater sympathetic activation. Therefore, decreasing anger 
rumination could decrease FMS symptom severity. Sukhodolsky´s hypothesis that 
forgiveness is negatively associated with anger rumination (51) is widely 
supported.  
Future research on the matter could focus on the question of the content of the 
anger rumination. Our results show that angry afterthoughts and angry memories 
play a preeminent role. Identifying those and then developing targeted programs 
which focus on attenuating their aftermath could lead to reduced angry rumination 
induced stress levels.   
 
 
6.5.2. Anger rumination and forgiveness 
Negative correlations between granting forgiveness and anger rumination have 
already been described. It became apparent that people who are more forgiving 
tend to ruminate less. And people who could decrease their anger rumination 
became more forgiving as demonstrated by Thompson et al (139), when they 
correlated the heartland forgiveness scale and the rumination scale of the 
response styles questionnaire.  
In our study, both subdimensions – self-forgiveness and other-forgiveness – 
correlate significantly with all anger rumination subscales. However, forgiveness 
of others showed a greater correlation with their mean scores, especially on 
thoughts of revenge. The same correlation was found in other studies as well (147). 
While it is inherent that being able to forgive means, in fact, to not exact vengeance 




indicates that the predominant thoughts of someone who cannot forgive are 
centered around getting even.  
The results of our study show that FMS patients struggle with more ruminative 
thoughts than healthy individuals and also indicate that forgiving could be key to 
resolving them. Ruminative thought reduction could be achieved. But aside from 
forgiveness, there are various techniques available to reduce perseverative angry 
rumination. Mindfulness and cognitive behavioral methods are among the most 
widely used (148). 
Mindfulness based stress reduction (MBSR) is the most widely used mindfulness 
intervention. MBSR focuses on being aware of the present moment, one´s 
feelings, thoughts and bodily sensations. Over the course of eight weeks, the 
participants are instructed in mindfulness meditation, body awareness and yoga 
postures. It has shown good efficacy in reducing ruminative thought in various 
studies (149,150).  
Cognitive-behavioral therapy is based on the premise that maladaptive cognitions 
perpetuate mental disorders and psychological distress. CBT is the umbrella term 
for a number of interventions designed to modify these cognitions in order to attain 
better mental health. The interventions involve a number of steps which are 
supposed to help the patients replace negative distortions such as 
overgeneralizations, excessive focus on negative aspects with a more accurate 
and wholesome appraisal of a situation (151).  
 
 
6.5. Limitations  
Although the results of this study reveal important details on the relationship 
between forgiveness, anger and angry rumination in FMS patients, some 
limitations are acknowledged.  
First, the external validity is limited because the results were generated by a FMS 
patient sample which was predominantly female. The disparity in proportional 
gender representation was expected as FMS affects mostly women. However, the 




gender differences.  Also, the results rely entirely on data collection through self-
assessment questionnaires. As no intervention was conducted, the comparative 
analyses only reveal correlations. Therefore, no predication regarding a causal 
direction can be made.  
 
 
7. Conclusion  
The results of this study show that FMS patients tend to be less forgiving compared 
to healthy individuals, especially when it comes to forgiving their own 
transgressions. Also, they seem to be struggling with high levels of anger and 
angry rumination. Forgiving and experiencing anger seem to be linked to the health 
status in FMS patients. Those who are inclined to a self-forgiving attitude appear 
to be less prone to anger and angry rumination and have a better physical 
functioning and a better quality of life. At this time there is no curative therapy 
available for FMS. Unimodal treatments like exercise therapy or medication show 
little effects that are not satisfying for most patients. Multimodal therapy seems to 
be more effective but the effects in most patients are still small. In search of a more 
comprehensive therapeutic approach, self-forgiveness and anger could be 
anchors on which to develop new therapeutic concepts for patients with FMS. 
Once effective forgiveness interventions have been established, they could be 
added to already existing multimodal treatment programs. 
To provide the scientific foundation, future studies should examine the efficacy of 
therapies based on promoting forgiveness and reducing anger. A longitudinal 
study, for example, in which anger, anger rumination, stress, physical functioning 
and quality of life are assessed in the course of a medium-term forgiveness 
intervention could further elucidate the correlations relationships presented in this 
dissertation. It would be thrilling to explore whether forgiveness increased by an 
intervention could lead to reduced stress levels and consequently to improved 
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